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2. Abstract 
 
Background and aims: Vascular anomalies constitute a challenging patient group. 
Their pathogenesis and risk factors are understood only in part. Their management 
has dramatically developed during the last 20 years. The objective of this study was to 
examine the mode of inheritance of and the risk factors for infantile haemangioma 
(IH), the most common vascular anomaly, and to analyse the treatment complications 
of sclerotherapy, the current first-line treatment for venous malformations (VM). 
 
Patients and methods: For the IH studies, we included all IH patients who had 
visited Helsinki University Hospital’s vascular anomaly clinic in 2004-2007. We 
collected data from hospital records on IH characteristics, complications, and 
interventions, and the child’s perinatal data when available. We sent these patients 
and their caregivers a questionnaire on perinatal data, child’s diseases, family history 
of IH, and the current subjective long-term discomfort due to IH. Perinatal and 
gestational data was compared to the Finnish Medical Birth Register data from the 
same catchment area in 2004-2007. Families reporting positive family history of IH 
were interviewed by phone to elucidate the pedigrees and inheritance patterns. For 
studies on sclerotherapy for VMs, we included all VM patients who had received 
sclerotherapy in our unit between 2007-2013. We recorded retrospectively VM 
characteristics, procedural data, and sclerotherapy complications, and analysed factors 
predisposing to complications. We graded complications from I to V according to the 
Clavien-Dindo classification for complications. 
 
Results: In addition to known IH risk factors, this study showed that preterm birth 
promotes ulceration of IH. Maternal gestational diabetes mellitus rate was 
significantly higher in our IH cohort than in the catchment area of our hospital 
district. One-third of IH patients reported a positive family history of IH. The 
inheritance pattern followed the autosomal dominant pattern, but in ten families, the 
transmission may also have been maternal. IH characteristics were similar in familial 
and sporadic cases. 
 
Of the head and neck venous malformations, 17% suffered from sclerotherapy 
complications. These patients needed overall more sclerotherapies, but also more 
surgery after sclerotherapy, and longer follow-up than those without a complication. 
Complication rate per procedure was 10%. Three treatment complications were 
severe, grade IIIb-IV, and necessitated surgical management and intensive post-
complication care. Of the trunk and extremity VMs undergoing sclerotherapy, 24% 
suffered from complications. Complication rate per procedure was 13%. The use of 
ethanol and subcutaneous location predisposed to local complications. Four severe, 
grade IV to V complications occurred, one of which was lethal. Severe complications 
were related to blood coagulopathy.  
 
?? ?
Conclusions: Our results imply that the role of maternal gestational diabetes as a 
potential IH risk factor is unclear and deserves further studies. Preterm IH infants’ 
higher risk for ulceration is a relevant concern for physicians treating IH-children. In 
addition to autosomal dominant inheritance, a relevant proportion of the familial IHs 
may be maternally transmitted. Complications of sclerotherapy for VMs mostly 
recover with conservative treatment, but severe complications do occur. Associated 
blood coagulopathy constitutes a major risk for the treatment. Interdisciplinary 
assessment of the treatment strategy is therefore crucial.   
 
 
Tiivistelmä 
 
Väitöskirjan tavoitteena oli selvittää infantiilin hemangiooman, lapsuusajan yleisim-
män kasvaimen, riskitekijöitä ja perinnöllisyyttä, sekä tutkia skleroterapian, 
laskimoepämuodostuman ensilinjan hoitomuodon, turvallisuutta. 
 
Hemangiooma-aineisto koostui potilaista, jotka olivat käyneet vuosina 2004-2007 
Helsingin yliopistollisen keskussairaalan (HYKS) Lastenklinikan suoniepä-
muodostumapoliklinikalla. Potilastietojen ja kyselykaavakkeen perusteella selvitettiin 
hemangiooman ominaispiirteet, komplikaatiot, hoidot, muut sairaudet, raskaus- ja 
syntymätiedot, hemangiooman esiintyminen suvussa ja hemangioomasta aiheutuva 
myöhäishaitta. Potilaiden raskaus- ja syntymätietoja verrattiin Terveyden ja hy-
vinvoinnin laitoksen syntymärekisterin tietoihin. Perinnöllisten hemangioomatapaus-
ten perheet haastateltiin periytymismallien tunnistamiseksi. Tutkimuksessa havaittiin, 
että ennenaikainen syntymä altistaa hemangiooman haavautumiselle. Tunnettujen 
riskitekijöiden lisäksi havaittiin, että hemangioomalasten äideillä oli esiintynyt 
enemmän raskausdiabetesta verrattuna syntymärekisterin tietoihin. Kolmasosalla 
potilaista esiintyi hemangioomaa suvussa. Hemangiooman ominaispiirteissä ei ollut 
eroa perinnöllisten ja ei-perinnöllisten tapausten välillä. Hemangiooma periytyi 
pääasiallisesti autosomissa vallitsevasti. Tutkimuksessa havaittiin lisäksi sukuja, 
joissa periytymismalli saattoi olla maternaalinen eli äidiltä periytyvä. 
 
Laskimoepämuodostuma-aineisto koostui HYKS:ssa vuosina 2007-2013 skleroterapi-
alla hoidetuista potilaista. Sairaalan rekisteristä analysoitiin retrospektiivisesti 
komplikaatiolle altistavia tekijöitä. Komplikaatiot arvioitiin Clavien-Dindo -luokituk-
sen mukaan. Skleroterapiaan liittyviä komplikaatioita esiintyi 17%:lla pään ja kaulan 
laskimoepämuodostumapotilaista, joista 4%:lla komplikaatiot olivat vakavia. 
Hoitokertakohtainen komplikaatioriski oli 10%. Komplisoituneissa tapauksissa tarvit-
tiin enemmän hoitokertoja ja skleroterapian jälkeistä kirurgiaa verrattuna 
komplisoitumattomiin tapauksiin. Raajojen ja vartalon laskimoepämuodostumapoti-
laista 24%:lla esiintyi komplikaatio skleroterapiassa. Hoitokertakohtainen komplikaa-
tioriski oli 13%. Etanolin käyttö skleroterapiassa sekä epämuodostuman ihonalainen 
sijainti altistivat paikallisille komplikaatioille. Seuranta-aikana esiintyi neljä henkeä 
?? ??
uhkaavaa komplikaatiota, jotka johtuivat vakavasta hyytymisjärjestelmän häiriöstä. 
Yhdessä tapauksessa vaikea hyytymiskomplikaatio johti potilaan kuolemaan.  
 
Tämän väitöskirjan osatöiden perusteella todetaan, että ennenaikaisesti syntyneet lap-
set ovat alttiimpia hemangiooman haavautumiselle. Raskausdiabeteksen yhteys lapsen 
riskiin saada hemangiooma vaatii lisäselvityksiä. Perinnöllisyystutkimusten perus-
teella hemangiooma saattaa periytyä sekä autosomissa vallitsevasti että mater-
naalisesti. Skleroterapia on pääasiallisesti turvallinen hoitomuoto laskimoepä-
muodostumaan. Etanolin käyttöä skleroterapiassa tulee välttää. Laskimoepä-
muodostumaan liittyvä hyytymishäiriö voi altistaa potilaan henkeä uhkaavalle 
hoitokomplikaatioille.  
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3. Abbreviations 
 
ATII: Angiotensin II 
AVM: Arterio-venous malformation 
CH: Congenital haemangioma 
CI: Confidence interval 
CM: Capillary malformation 
CVS: Chorionic villus sampling 
DIC: Disseminated intravascular coagulopathy 
EPC: Endothelial progenitor cells 
FMBR: Finnish Medical Birth Register 
GDM: Gestational diabetes mellitus 
GLUT-1: Glucose transporter protein isoform 1 
H&N: Head and neck 
HUH: Helsinki University Hospital 
ICD: International Classification of Diagnosis 
IH: Infantile haemangioma 
ISSVA: International Society for the Study of Vascular Anomalies 
IVF: In vitro fertilization therapy 
KHE: Kaposiform haemangioendothelioma  
LM: Lymphatic malformation 
LMWH: Low-molecular-weight heparin 
LUMBAR: Lower body infantile haemangioma, urogenital anomalies, 
myelopathy, bony deformities, anorectal malformations and arterial 
anomalies, renal anomalies 
MRI: Magnetic resonance imaging 
NICH: Non-involuting congenital haemangioma 
OR: Odds ratio 
PDL: Pulse dyed laser 
PE: Preeclampsia 
PHACES: Posterior fossa malformations, haemangioma, arterial anomalies–
cardiac defects, eye abnormalities, sternal cleft and supraumbilical raphe 
syndrome 
PICH: Partly-involuting congenital haemangioma 
RAS: Renin-Angiotensin system 
RICH: Rapidly involuting congenital haemangioma 
STS: Sodium tetradecyl sulphate 
T&E: Trunk and extremity 
TA: Tufted angioma 
THL: Finnish National Institute of Health and Welfare 
US: Ultrasonography 
VAS: Visual analogue scale 
VEGF: Vascular endothelial growth factor 
VM: Venous malformation 
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4. Introduction  
 
Congenital vascular anomalies constitute a diverse group of mostly benign vascular 
lesions mainly occurring in children and adolescents (1,2). These anomalies are 
divided into vascular tumours and vascular malformations (1-5). The most common 
vascular tumour is infantile haemangioma (IH), and the most common vascular 
malformation is venous malformation (VM) (1,4,6-9). Vascular anomalies typically 
reside in the head and neck area (4,10,11). Clinical image of vascular anomalies 
varies dramatically from small innocuous vascular lesions to large, diffuse, invasive 
vascular lesions that may cause substantial disfigurement, functional problems, 
coagulopathy, and severely disturb the cardiovascular system (4). Therefore their 
treatment strategy highly depends on the diagnosis and the extent of morbidity they 
cause.  
 
For IH, risk factors are relatively well documented, but the genetic background 
remains largely unsolved (6,9,12,13). For VMs, the TIE2 mutation, and some other 
genetic alterations are causative in most patients (10,14). Because most vascular 
anomalies are benign, to guarantee treatment safety is essential.  
 
This dissertation will focus on the most common vascular anomalies: infantile 
haemangioma and venous malformation. The first main objective is to study the risk 
factors and inheritance of IH.  The second main objective is to study the 
complications of sclerotherapy, the current first-line treatment for VMs.  
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5. Review of the literature 
 
5.1. Overview of vascular anomalies  
 
5.1.1. Terminology and classification 
The term ‘Vascular anomaly’ covers a large, heterogeneous group of vascular lesions 
and birthmarks that range from innocuous lesions to large, life-threatening vascular 
masses causing severe discomfort, organ dysfunction, cardiac compromise, and 
coagulopathy (1,4). The nomenclature for vascular anomalies has long been 
inaccurate, leading to misunderstanding, improper or delayed diagnosis and treatment. 
The terms ‘haemangioma’, ‘cavernous or capillary haemangioma’ have been applied 
to a variety of vascular lesions that actually imply other vascular lesions than the 
typical infantile haemangioma. Figure 1 shows different vascular anomalies. 
Expanding knowledge of vascular anomalies and systematic work of interdisciplinary 
vascular anomaly teams has led to a more precise classification system (1,2,5,15-17).  
 
 
Figure 1. Various types of vascular lesions. A. Congenital haemangioma. B. Infantile 
haemangioma. C. Lymphatic malformation. D. Infantile haemangioma. E. Pyogenic 
granuloma. F. Capillary malformation.   
 
 
 
 
B. A. C. 
D. E. F. 
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Mulliken and Glowacki introduced the first classification of vascular anomalies based 
on their endothelial and growth characteristics that distinguished vascular tumours 
and malformations in 1982 (1-3). Thereafter, this classification has been updated 
several times due to the increasing understanding of vascular anomalies (5,18,19).  
The current classification, established by the International Society of the Study of 
Vascular Anomalies (ISSVA), was updated in 2014, and is summarised in Table 1 
(5). As an advantage compared to previous updates, the classification now takes into 
account not only the cellular and growth characteristics, but also the behaviour of the 
lesion. The ISSVA classification functions as a framework for the diagnostic 
challenges, and it should evolve by means of constantly expanding knowledge (5). 
Due to scarcity of knowledge, a group of vascular anomalies still remain unclassified, 
such as verrucous haemangioma, angiokeratoma, and angiomatosis of soft tissue, the 
latter also called PTEN hamartoma, due to its PTEN mutation (5).  
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Table 1. Classification of vascular anomalies adapted from the ISSVA 2014 
classification (5). Reprinted with the permission of the American Academy of 
Pediatrics, from Wassef et al. “Vascular Anomalies Classification: Recommendations 
From the International Society for the Study of Vascular Anomalies.” Pediatrics. 2015 
Jul;136(1):e203-14. 
 
Classification of Vascular Anomalies 
Behaviour Vascular 
Tumours 
Vascular Malformations 
  Simple Combined Of 
Major 
Named 
Vessels 
Associated 
with other 
anomalies 
Benign IH 
CH  
Tufted 
angioma 
Pyogenic 
granuloma 
Others 
CM    
Locally 
Aggressive 
or 
Borderline 
Kaposiform 
haemangio-
endothelioma 
Others 
VM 
LM 
CM+VM 
CM+LM 
CM+LM+VM 
LM+VM 
Truncu-
lar 
Klippel-
Trenaunay 
Parkes-Weber 
(CM+AVF) 
Sturge-Weber 
(CM) 
Others 
Malign Angio-
sarcoma 
Kaposi 
sarcoma 
Ephitelioid 
haemangio-
endithelioma 
AVM 
AVF 
CM+AVM 
CM+LM+AVM 
CM+VM+AVM 
 CLOVES 
Others 
Abbreviations: AVF: Arteriovenous fistula; AVM: Arteriovenous malformation; CH: 
Congenital haemangioma; CLOVES: Congenital, lipomatous, overgrowth, vascular 
malformations, epidermal nevi and spinal or skeletal anomalies; CM: Capillary 
malformation; IH: Infantile haemangioma; LM: Lymphatic malformation; VM: 
Venous malformation 
 
 
 5.1.2.  Vascular tumours 
Vascular tumours are characterized by endothelial proliferation and by aberrant blood 
vessel growth and architecture (1-3). The most common vascular tumour is infantile 
haemangioma (IH), which is the most common tumour of childhood (Figure 2) (1,4).  
Histologically IH is distinct from other benign vascular tumours and malformations: 
only IH stains positive with glucose transporter protein isoform 1 (GLUT1) antigen 
?? ??
(20). For the epidemiology, pathogenesis, clinical course, associated syndromes, and 
management of infantile haemangioma, see section 5.2. In addition to IH, other 
vascular tumours comprise congenital haemangioma, pyogenic granuloma, tufted 
angioma, and haemangioendothelioma (2,5,18).  
 
 
Figure 2. Typical infantile haemangioma of the arm, A., and forehead, B. 
 
 
 
 
Congenital haemangioma (CH) differs from IH in its histopathology and its growth 
characteristics: CH is fully developed at birth, after which it can follow three different 
involution patterns. Rapidly involuting congenital haemangioma (RICH) starts to 
involute shortly after birth, reaching full involution by the first year of life (Figure 3) 
(21). Non-involuting congenital haemangioma (NICH) represents the other extreme 
of congenital haemangioma, as it is fully formed at birth, but it neither involutes nor 
grows thereafter (22,23). Some congenital haemangiomas show some but not full 
involution and are categorized as partly-involuting congenital haemangiomas (PICH) 
(24,25). Congenital haemangiomas are less prevalent than IHs. All CHs stain negative 
with GLUT1 (26). RICH, when large in volume, can sometimes lead to transient 
thrombocytopenia and cardiac compromise (27).  
 
 
 
 
 
 
 
A.  B.  
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Figure 3. Rapidly involuting congenital haemangioma after birth, A., at age 5 
months, B., and at age 12 months, C. 
 
 
 
 
Pyogenic granuloma is defined as a reactive, acquired, proliferative vascular lesion, 
often appearing in the head and neck region (Figure 4A). It grows quickly to its 
maximal size and often manifests a pedunculated base. Almost half of all pyogenic 
granulomas appear during the first 5 years of life (28).  
 
Tufted angiomas (TA, Figure 4C) are benign vascular tumours, mostly located in the 
neck or upper thorax. TAs sometimes mimic IH; however, they neither show such 
clear growth and involution pattern as IH nor do they stain with GLUT1 antigen 
(26,29,30). Kaposiform haemangioendothelioma (KHE, Figure 4B) is a locally 
aggressive vascular tumour that like a TA, exhibits an unpredictable growth pattern. It 
appears often in deeper soft tissues, and is GLUT1 negative (31,32). Both KHE and 
TA may lead to severe consumptive coagulopathy and thrombocytopenia, also known 
as the Kasabach-Merrit phenomenon (30-34). Rare malignant vascular tumours 
include Kaposi sarcoma and angiosarcoma, which should be considered as differential 
diagnoses in non-typical cases.  
 
 
 
 
 
 
 
 
 
 
A.  C.  B.  
?? ??
Figure 4. Other vascular tumours: A. Pyogenic granuloma B. Kaposiform 
haemangioendothelioma C. Tufted angioma. 
 
 
 
 
5.1.3.  Vascular malformations 
Vascular malformations comprise vascular lesions resulting from errors in vascular 
morphogenesis. They are present, but not necessarily visible, at birth; they grow 
according to their specific nature and almost never regress (1-3). Vascular 
malformations can be divided according to the vessel type they exhibit, as venous, 
capillary, lymphatic, or arteriovenous malformations, or according to the complexity 
of the lesion, as simple or combined malformations (Table 1). The rare group of 
malformations of major named vessels consist of vascular structures that involve 
major axial vessels, including also persistent embryonic vessels and congenital 
arteriovenous fistulas (1,5,18). 
 
5.1.3.1. Simple vascular malformations 
Capillary malformations (CM) are mostly benign and consist of morphologically 
anomalous capillary structures (Figure 5). They affect mostly skin or mucosa and are 
often called port-wine stains. CM has an estimated incidence of 0.3% (35). They are 
most often present at birth, normally persist throughout life, and may cause thickening 
or darkening of the skin, even though some lesions may also fade away over time. A 
small number of CMs are related to syndromes: CMs covering large areas of a limb 
may also involve other vascular malformations and soft tissue or bone overgrowth, 
i.e. in Klippel-Trenaunay or Parkes-Weber syndromes; large facial CMs may 
associate with Sturge-Weber syndrome (Table 1) (2,4,5).   
 
 
 
 
 
 
 
C.  A.  B.  
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Figure 5. A. Capillary malformation of the face. B. Capillary malformation 
associated with overgrowth of the lower limb.  
 
 
 
 
Venous malformations (VM) are low-flow lesions consisting of anomalous dilated 
veins that can affect any tissue or organ (Figure 6). They are the most common type 
of vascular malformations. Large VMs may result in local intravascular coagulopathy 
that may constitute major symptoms and cause treatment challenges (2,4,5). Venous 
malformations will be further discussed in section 5.3. 
 
 
Figure 6. A large venous malformation (VM) in the sclera, extending into the orbit 
and cheek, A. An MRI of the same lesion, B. 
 
 
 
 
A. B.
A. B. 
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Lymphatic malformations (LM, Figure 7) are low-flow vascular malformations that 
comprise anomalous and differently dilated lymphatic channels filled with lymphatic 
fluid (4). They occur approximately at an incidence of 3 per 100 000 individuals 
(36,37). LMs can be further divided into macro-, or microcystic, or mixed lesions 
(1,4,38). Macrocystic LMs manifest as large fluid-filled cystic lesions, whereas 
microcystic lesions are comprised of several smaller cystic spaces. Approximately 
75% of all LMs are located in the head and neck area and are usually diagnosed 
before the age of two (4,38,39).   
 
 
Figure 7. A typical macrocystic lymphatic malformation of the neck, A., and a T1-
weighted, B., and T2-weighted, C., MRI image of the same lesion. 
 
 
 
 
Arteriovenous malformations (AVM) are high-flow vascular lesions and exhibit 
typically an aggressive growth behaviour (Figure 8). Their exact incidence and 
prevalence are as yet undefined (40). AVMs consist of morphologically anomalous 
arteries, veins, and capillaries in which arteriovenous shunting is present. They are 
pulsating, warm vascular lesions leading to ulcerations, bleeding, and potentially 
severe tissue disfigurement. AVMs often progress during pregnancy as the systemic 
blood volume increases. Due to the shunting and venous overload, AVMs, if left 
untreated, may result in cardiac compromise. Some AVMs are related to a mutation in 
the RASA1 gene (1,2,4,41).  
 
 
 
 
 
A.  B.  
C.  
?? ??
Figure 8. An arteriovenous malformation (AVM) of the chin and base of the mouth, 
A. An angiograph shows the anomalous circulation in this lesion, B. 
 
 
 
 
 
5.1.3.2. Combined vascular malformations 
Combined vascular malformations may comprise combinations of any of these 
malformation types. The most common combined malformations are capillary-venous 
malformation (CM+VM), lymphatic-venous malformations (LM+VM), or capillary-
lymphatic-venous malformations (CM+LM+VM). Combined vascular malformations 
may be associated with different syndromes (1,2,4,5).   
 
5.1.3.3. Malformations associated with syndromes  
A small number of vascular malformations involve also other anomalies as well, or 
are associated with syndromes that usually lead to deterioration in the patients’ 
condition. These syndromes include Klippel-Trenauanay syndrome (limb overgrowth 
due to a combined malformation CM + VM +/- LM), shown in Figure 9, Parkes-
Weber syndrome (limb overgrowth and a combined malformation, CM + AVF), 
Sturge-Weber syndrome (facial and leptomeningeal CM with ocular anomalies and 
possible bone or soft tissue overgrowth), and CLOVES syndrome (congenital, 
lipomatous overgrowth, vascular malformations, epidermal nevi, and spinal or 
skeletal anomalies), and a number of other rare syndromes (Table 1). The distinctions, 
diagnostics, and management of these syndromes call for the expertise of an 
interdisciplinary vascular anomaly team (5,15,42).  
 
 
 
 
 
A. B. 
?? ??
Figure 9. A child with Klippel-Trenauanay syndrome. 
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5.2. Infantile Haemangioma 
 
5.2.1.  Definition 
Infantile haemangioma is a benign vascular neoplasm that most commonly locates in 
the skin and subcutaneous tissue but may be found in any tissue or organ. It consists 
of proliferating endothelial cells that line the variable-sized blood vessels that form 
this vascular tumour.  Peculiar to infantile haemangioma is its life cycle: it appears 
shortly after birth and may proliferate up to one year of age, after which it starts 
spontaneously to regress (1-3).   
 
5.2.2. Epidemiology  
Infantile haemangioma is the most common soft tissue tumour of childhood. Its 
incidence is estimated at between 2 and 10%; these estimates are based on different 
study populations and various study settings. IH is considered more common in 
Caucasian infants (1,4,6-9,43). A recent register-based study conducted in Minnesota 
estimated IH’s incidence to be 2% (44). A Dutch study reported an IH prevalence of 
9.9% (6). The incidence and prevalence of IH in the Finnish population is unclear. 
Karvonen and colleagues reported vascular birthmarks to appear at a frequency of 
3.8% in infants aged 0 to 3 months, but this study did not differentiate IHs from other 
vascular lesions (45). IHs are more common in females: the male-to-female ratios 
vary from 1:1-3 (6,12). Other host-related risk factors include preterm birth and low 
birth weight, which is considered the strongest determinant (4,12,44,46). Prenatal and 
mother-related risk factors, shown in Table 2, include advanced maternal age, 
multiple gestations, in vitro fertilization therapy, placenta praevia, preeclampsia, 
transcervical chorionic villus sampling, and amniocentesis, even though reported risk 
factors vary depending on study setting and population (6,8,9,12,47-52). However, 
most of these risk factors relate to intrauterine hypoxia, which has been considered a 
major player in IH’s pathogenesis (53). Familial clustering is one reported risk factor 
(12,54). Atopic disease has been positively associated with IH (55).   
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Table 2. Summary of risk factors for IH in earlier studies. Significant risk factors (+), 
and non-significant risk factors (-) for each study. Study settings are classified as 
prospective (P) or case-control (CC). 
 
IH risk factors 
P 
Munden 
et al. 
USA 
(n=29) 
CC 
Rasul  
Uzbekistan 
(n=1832) 
CC 
Chen et 
al. 
China 
(n=650) 
CC 
Hoornweg 
et al. 
Netherlands 
(n=219) 
P 
Dickinson 
et al. 
Australia 
(n=28) 
P 
Haggstrom 
et al. 
USA 
(n=1058) 
Host-related        
Female - - + + + + 
Family history 
of IH na + na na + - * 
Gestational        
Multiple 
pregnancy na + + na - + 
Chorionic 
villus sampling na - - na - - 
Amniocentesis na na na + na na 
Placenta 
praevia  + - na na na + 
Preeclampsia  + - - -  ** na + 
Perinatal        
Preterm  + - + na + + 
Very preterm  + na na na na + 
Birth weight 
<2500g + - + + + + 
Maternal        
Maternal age 
≥35 years - - - na na + *** 
First childbirth na - - + na na 
In vitro 
fertilization na - + na + na 
Abbreviations: n: number of IH patients studied; na: not available; Preterm: <37 
gestational weeks; Very preterm: < 32 gestational weeks or birth weight < 1500g. * 
First-degree relatives with haemangioma. ** Maternal hypertension. *** Maternal 
age ≥30. 
 
 
5.2.3.  Pathogenesis 
IH pathogenesis has been under extensive study, but it is nevertheless only partly 
understood. The current consensus is that an IH derives from the embryonic-like 
progenitor cells that constitute the original source for endothelial cells in IH. These 
cells need an adequate cellular environment and external factors to develop an IH 
(56). The two main theories of the origin of these progenitor cells are these: that they 
are derived from circulating endothelial progenitor cells (EPC) or are derived from 
placental cells.  
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 The EPC theory holds that an IH is a clonal tumour developed from intrinsic 
circulating endothelial progenitor cells that find an appropriate growth environment 
for vasculogenesis. The stimulus for EPC proliferation remains unclear: it may be 
hypoxia, a genetic factor, or a proliferation-prompting signal from surrounding tissues 
(57,58). This theory is reinforced by the finding of elevated levels of circulating EPCs 
in IH children undergoing surgical resection compared to age-matched controls 
(59,60). Moreover, research shows that IH-specimen-derived multipotential stem cells 
are capable of forming haemangioma in immunodeficient mice. These stem cells 
share characteristics with cord blood EPCs. EPCs are therefore suggested to be the 
origin of IH stem cells (61).  
 
The placental theory, on the other hand, receives support from the finding that IH 
endothelium expresses many of the tissue markers expressed also in placental cells 
such as GLUT1 and other placental-specific markers (20,62-64). A recent study has 
revealed very similar expression between the proliferating endothelium of IH and 
placental chorionic villus mesenchymal core cells, hypothesizing that these cells are 
the origin of IH stem cells. The potential embolization of placental cells may either 
coincide with the first trimester’s migration of neural crest cells along their somatic 
group, likely to result in segmental IH lesions, or be a result of embolization later in 
gestation, which may lead to focal or indeterminate IH lesions (65). The placental 
theory would also explain the higher incidence of chorionic villus sampling and 
amniocentesis in IH children’s mothers, as these procedures can cause minimal 
disruption of placental cells and therefore promote the embolization (48,49,66).  
 
Regardless of the origin of IH progenitor cells, they exhibit markers of primitive 
embryonic-like stem cells, thus giving further rise to the various cell groups of IH 
(61,67-71). The trigger for IH stem cells to proliferate and to differentiate is only 
understood in part: pro-angiogenic, pro-vasculogenic and anti-apoptotic factors may 
favour haemangiogenesis (56). Recent research emphasizes the role of the renin-
angiotensin system (RAS) as the main regulator of haemangiogenesis: elevated renin 
levels result indirectly in high angiotensin II (ATII) levels that promote the cellular 
proliferation of IH (72,73). This effect is achieved by the capacity of ATII to activate 
vascular endothelial growth factor (VEGF) and anti-apoptotic osteoprotegrin (74,75). 
The VEGF-A isoform has been reported to play a crucial role in endothelial 
proliferation. It is highly sensitive to hypoxia and promotes angiogenesis and 
vasculogenesis (13,76-78).  
 
To escape apoptosis, an up-regulation of the anti-apoptotic osteoprotegrin, a receptor 
for tumour necrosis factor-related pro-apoptotic ligand and a pro-tumour survival 
factor, has been observable in proliferating IHs. Logically, involuting IHs manifest 
reduced levels of osteoprotegrin, coinciding with the apoptosis of endothelial cells 
(79). Insulin-like growth factor 2 is reportedly expressed and produced by 
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proliferating endothelium of IH, most likely contributing as a growth factor, whereas 
reduced expression levels are apparent in involuting IHs (80,81).  
 
The role of RAS as a crucial mediator in IH’s pathogenesis coincides with the known 
IH risk factors: elevated levels of renin occur in females, in Caucasians, and in 
premature infants (74). Additionally, the physiological changes in renin levels during 
infancy also correspond well to the life-cycle of IH: up to 3 months of age, newborns 
exhibit five-fold serum levels of renin compared to those in adults, coinciding with 
the most rapid proliferation phase. Then, renin-levels decrease to three-fold at ages 3 
to 12 months, coinciding with the late proliferative phase; to two-fold at 1 to 4 years, 
corresponding to the plateau and involution phase, and eventually from 8 years 
onwards renin levels decrease to adult levels (82). The importance of RAS as a crucial 
mediator is further supported by the current therapeutic approach for IHs: β-blockers 
reduce renin levels and therefore restrict IH proliferation (72,83). Additionally, 
captopril, an angiotensin-converting enzyme inhibitor, has been introduced into the 
treatment of IH (74,84). Comprehensive understanding of IH pathogenesis provides 
better tools for IH treatment. 
 
5.2.4.  Genetics 
Despite extensive research, understanding of genetics in the development of IH 
remains limited. Most IHs occur sporadically, but familial clustering does occur, and 
family history of IH is regarded as a risk factor. Walter, Blei, and colleagues reported 
a subset of six families that showed an autosomal dominant IH inheritance pattern 
with high penetrance; in three of these families they showed a linkage to chromosome 
5q31-33 (85,86). A population-database study in Utah reported a two-fold increase in 
relative risk for IH in siblings of an IH-affected proband, supporting familial 
predisposition as a risk factor (54). Children from multiple gestations have more IH; a 
recent prospective multicentre cohort study on 202 sets of twins showed, however, 
that concordance of IH between mono- and dizygotic twins was similar, and rather 
emphasized its multifactorial origin (87,88).  
 
Mutations in genes regulating angiogenetic and vasculogenetic signalling pathways 
have been proposed as causative for IH in small patient cohorts: Jinnin and colleagues 
found germline missense mutations in proliferating haemangioma-derived endothelial 
cells in VEGFR2 and TEM8 genes, leading to inhibited integrin activity. They also 
speculated that a second event, either a somatic mutation or a physiological trigger, is 
necessary for IH progression (78). Walter and colleagues found missense mutations in 
single IH specimens in VEGFR2 and VEGFR3 (89). Clonality assays support a non-
random X-chromosome inactivation in IH endothelial cells, suggesting a clonal origin 
for the tumour (57,89,90). The genetic variants - either somatic or germline - playing 
a role in IH pathogenesis in concordance with other physiological risk factors, remain 
as yet mostly unsolved (91).  
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5.2.5.  Histopathology 
The histology of IH varies dramatically depending on its stage. A proliferating IH 
consists of defined, unencapsulated capillary masses, aligned with endothelial cells 
and supporting pericytes. The cells reside in a multilaminated basement membrane 
with no association with smooth muscle cells. Mitotic activity is usually ample but 
benign. Due to the high-flow feature in proliferating IHs, yet mostly without 
arteriovenous shunting, enlarged and unorganized draining veins are often present. In 
contrast, involuting IHs exhibit few mitotic figures, apoptotic cell bodies 
accompanied by mast cells, and a reduced number of capillaries. These tissue 
structures are eventually replaced by fat cells (1,26,92). Characteristic of IH is the 
staining with GLUT1 antigen, a widely used immunohistochemical marker to 
distinguish IHs from other benign vascular tumours and malformations (Figure 10) 
(20). Of note, a rare verrucous haemangioma and some malignant tumours such as 
angiosarcoma also stain positive with GLUT1, emphasizing that the IH diagnosis 
should not only be based on GLUT1-positivity (20,93).  
 
 
Figure 10. GLUT1-antigen-positive IH specimen. 
 
 
 
 
 
5.2.6 Clinical presentations  
5.2.6.1. Clinical course 
IH’s clinical manifestation and typical life cycle make it relatively easy to distinguish 
IH from other vascular tumours and malformations. By definition, IHs are not present 
at birth; however, they may show blanching or local erythema that precedes their 
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initial onset (1,4). In early infancy, the IH starts its proliferation, during which it 
enlarges and reaches its typical configuration (94,95). Due to rapid proliferation, the 
surface of an IH may also ulcerate. The most rapid proliferation typically occurs early 
in infancy: 80% of IH growth is reached by 3 months of age, and by 5 months of age 
most IHs complete their growth (94). Superficial IHs tend to show an earlier onset of 
proliferation and growth completion, whereas deep IHs usually appear later and 
continue to grow longer.  The proliferation phase of IH is typically completed by 12 
months of age (4,96,97).  
 
Between the proliferation and involution lies a plateau phase, during which 
proliferation and apoptosis are balanced (4,94,96,97). The involution phase usually 
begins at age 6 to 12 months, proceeds until age 10 to 12 years, yet major regression 
is usually reached by the age of 4. Involution often occurs by flattening of the IH from 
the centre outward (98-100). Despite their spontaneous involution, most IHs leave 
behind residual skin changes such as teleangiectasia, scarring, dyspigmentation, or 
fibrofatty tissue residue (Figure 11) (101).  
 
 
Figure 11. Involution of a typical focal IH of the forehead. A. IH at age 6 months. B. 
At 1.5 years. C. At 2 years. D. At 5 years. 
 
 
 
 
A. B. 
D. C. 
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5.2.6.2. IH localisation and subtypes 
Approximately 60% of IHs occur in the head and neck area. The second most 
common localization is the trunk, followed by limb manifestations (1,4). IH 
localisation is a major factor regarding each lesion’s clinical importance and 
morbidity. Other major determinants are size, number of lesions, the soft-tissue depth, 
and the anatomic morphology (43,102).  
 
Most IHs reside in the skin, and are categorized as cutaneous or superficial. They 
appear as red, “strawberry-like” lesions, with very little or no subcutaneous 
component. Superficial IHs usually follow an early-onset proliferation and involution 
pattern. Deep IHs, in contrast, reside subcutaneously, manifesting either a slight 
bluish surface or no surface coloration at all. Some IHs show both superficial and 
deep components and are therefore called mixed lesions (1,4,97,101).   
 
IH morphological subtypes are classified as focal, multifocal, indeterminate, or 
segmental (Figure 12) (43,103-105). The focal subtype is the most common (60-
70%), manifesting growth from a single focal point. Multifocal IHs, often classified 
as more than ten IH lesions, are rare but may associate with underlying hepatic 
haemangiomas (43). Five or more cutaneous lesions are considered as an indication 
for ultrasonography to check for hepatic IHs, as these may cause hepatomegaly and 
lead to congestive heart failure (106-108). The indeterminate subtype is the second 
most common, and occurs in approximately 17% of IHs: it shows clearly neither a 
focal nor segmental pattern (43).   
 
 
Figure 12. IH morphological subtypes. A. Segmental IH. B. Indeterminate IH. C. A 
child with multifocal IHs, only those on back are shown. 
 
 
 
 
Segmental IHs follow a developmental dermatome, and they tend to invade large 
areas; they are relatively rare (13%) but often cause significant burden to the child, as 
they are more prone to complications. They may be associated with other anomalies 
A. B. C. 
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(43,102). In the face, segmental haemangiomas are further classified according to 
their developmental distribution as frontotemporal, maxillary, mandibular, or 
frontonasal (43,105).  
 
Rarely, an IH may locate in the airways, especially in the supra- or subglottic area, 
causing inspiratory and expiratory stridor and potentially life-threatening airway 
obstruction during the first three months of life when proliferating (109-111). 
Children with an airway IH often manifest with a skin lesion: those with segmental 
IHs of the lower face in a “beard” distribution, especially bilaterally, covering the 
anterior neck, lower lip, and chin may have an underlying airway IH (Figure 13) 
(109-111). The exact incidence of airway IHs is unknown; Orlow and colleagues 
evaluated 529 children with IH, of whom 10 (2%) had an airway involvement, all of 
whom also manifested a cutaneous beard IH (109). When a child with a segmental 
facial or neck IH suffers from stridor, referral to an otorhinolaryngologist is therefore 
crucial to avoid delay in diagnosis of and treatment for any potential airway IH (112).    
 
 
Figure 13. Infantile haemangioma with a beard distribution, A. The patient also had a 
subglottic IH causing airway obstruction, B. 
 
 
 
 
5.2.6.3. IH complications 
Despite the usual benign clinical course, an IH may cause complications. Earlier 
studies estimated that 20 to 40% of IH children suffer from any kind of IH 
complications (51,102). Of note, those studies have been conducted in a referral 
centre setting, probably exaggerating the rate compared to the complication rate in a 
primary health care setting. Major factors affecting complication risk are IH subtype, 
size, and location. The segmental subtype is regarded as the best predictor for a 
complication: segmental IHs are reportedly 11-fold more likely to result in 
complications, and eight-fold more likely to receive treatment than are non-segmental 
IHs. The larger the IH, the higher is the risk for complications and intervention. A?
A. B. 
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facial location bears a 1.7-fold complication risk compared to other locations, and it 
also predicts the need for intervention (102).  
 
The most common IH complications are ulceration (5-21%), bleeding (up to 41%; 
severe bleedings are rare), and visual-axis compromise. Life-threatening 
complications such as cardiac compromise and airway obstructions are rare but 
possible (102,112). The nature of the complication often depends upon IH location 
and proliferation pattern. Predictors for IH complications are listed in Table 3. Figure 
14 shows possible IH complications.  
 
 
Table 3. Summary of IH complications (112).   
 
Complication  IH characteristic 
predicting 
complication 
Complication 
mechanisms 
Potential 
complication 
sequel  
Ulceration Segmental, 
superficial subtype; 
Head, neck, perioral, 
perianal location 
Tissue hypoxia, 
aggressive 
proliferation 
Scarring, 
disfigurement 
Bleeding  IH’s ulceration Surface trauma Scarring 
Visual impairment  Periocular, orbital or, 
nasal location  
Ptosis, eyelid 
margin change, 
displacement of 
the globe 
Amblyopia 
Auditory canal 
obstruction 
Periauricular and 
parotid gland 
location 
Anatomic 
distortion, 
cartilaginous 
destruction 
Conductive 
hearing 
impairment 
Airway obstruction 
Nasal cavity 
obstruction 
Airway IH, often 
present with “beard” 
IHs, nasal location 
Proliferation of 
IH narrowing the 
airways, or nasal 
cavity 
Life-threatening 
airway 
obstruction 
Feeding obstruction Lip or oral IH 
location 
Ulceration or 
obstruction 
leading to painful 
eating or 
swallowing 
problems 
Malnutrition 
Cardiac compromise 
 
Large size, 
aggressive IH 
proliferation, 
Multiple hepatic IHs 
Arteriovenous 
shunting 
Life-threatening 
cardiac 
insufficiency 
Acquired 
hypothyroidism 
Hepatic IH Increased 
production of type 
3 iodothyronine 
deiodinase 
Growth 
retardation, 
neurological 
deficit 
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Figure 14. Complications of infantile haemangioma (IH). A. IH ulceration. B. 
Periorbital IH disturbing the visual axis. C. Massive IH of the parotid gland resulting 
in cardiac compromise and auditory canal obstruction.   
 
 
 
 
5.2.6.4. IH-associated syndromes 
Even though rare, an IH may be a sign of an underlying syndrome that includes other 
congenital anomalies. Infants with a large facial IH (>5cm2) should be monitored for 
PHACES (Posterior fossa malformations, haemangioma, arterial anomalies–cardiac 
defects, eye abnormalities, sternal cleft, and supraumbilical raphe) syndrome. 
PHACES syndrome involves defects in the cerebrovascular system in 90% of the 
cases, structural brain anomalies in 52%, and cardiovascular, mostly aortic, anomalies 
in 67%. Children with PHACES may also have ocular anomalies, and ventral or 
midline defects such as sternal cleft or supraumbilical raphe (102,113). Peculiar to 
PHACES is a segmental facial haemangioma of the frontotemporal or mandibular 
area. The pathogenesis of PHACES is unclear, even though earlier research has 
suspected the chromosomal region of 7q33 as being causative (114). All PHACES-
derived defects can be explained by major developmental arterial vasculopathy, a 
possible key mechanism in PHACES pathogenesis (115). MRI imaging is indicated 
for children with large facial IHs to rule out this syndrome. In contrast to the typical 
IH risk factors mentioned, children with PHACES tend to be normal birth weight, 
full-term singleton infant (116).  
 
Another congenital syndrome associated with IH is LUMBAR, which stands for 
lower body IH, urogenital anomalies and ulceration, myelopathy, bony deformities, 
anorectal malformations and arterial anomalies, and renal anomalies. LUMBAR is 
often regarded as a variant of PHACES, but in the lower body. LUMBAR-associated 
IHs usually manifest as segmental, readily ulcerating lesions in the lumbosacral or 
anogenital area. LUMBAR may involve underdevelopment of the affected lower 
limb. MRI imaging is indicated for children exhibiting this type of IHs to reveal 
potential extracutaneous manifestations of LUMBAR (117).  
 
 
 
A.  C. B. 
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5.2.7. Diagnostic methods 
The diagnosis for IH is usually clinical and is based on typical appearance and clinical 
course. Imaging studies serve for IH diagnosis when the clinical diagnosis is 
uncertain, when the extent of IH needs accurate evaluation, when associated 
extracutaneous anomalies are suspected, or when monitoring of the therapy response 
is important. Potential diagnostic imaging tools include MRI and ultrasonography 
(Figure 15).  A biopsy is necessary only when the diagnosis is uncertain (5,112) 
 
 
Figure 15. An IH on the scalp at age two years, A., MRI T2-weighted fat-saturated 
image of the same lesion, B., and circulation on Doppler ultrasound, C. 
 
 
 
 
Ultrasonography (US) usually serves as an initial imaging modality, because it lacks 
ionizing radiation and requires no sedation. Depending on the IH’s proliferation 
phase, US findings include a well-defined soft-tissue mass with high-flow circulation 
and possible shunting, but later in the involution phase, areas of fat replacement are 
often present. US can also serve as a primary screening method for children with 
multifocal IHs that may have liver or visceral manifestations, although MRI is 
preferred for more complex cases (118).   
 
When the full extent of IH and its potential extracutaneous manifestations necessitate 
visualising, MRI serves as a primary diagnostic tool (Figure 16). The need for 
anaesthesia and its potential to damage a developing brain is, however, a major MRI 
drawback (119,120). On MRI, proliferating IHs manifest as well-defined high-flow 
masses and show some signal intensity on T1-weighted images and strong signal 
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intensity on T2-weighted images (121,122). When gadolinium is administered as a 
contrast medium, IHs usually exhibit enhancement and filling on early images (123).  
 
 
Figure 16. A typical MRI finding of a periorbital IH. A. Axial T2 fat-saturated image. 
B. Axial T1 fat-saturated image with gadolinium. C. and D. Coronal image T1 fat-
saturated with gadolinium. 
 
 
 
 
When the diagnosis remains unclear despite clinical examination and imaging studies, 
or when other vascular tumours or malignant conditions must be ruled out, biopsy and 
histopathological examination is necessary (5,112).  	
B. 
C. 
A. 
D. 
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5.2.8.  Treatment 
Due to IHs’ spontaneous regression, most lesions do not require treatment. 
Nevertheless, estimates show that approximately one-third of IHs need some kind of 
intervention, even though tertiary-centre study settings and referral bias may 
exaggerate these estimates (6,102). The commonly accepted indications for 
intervention include a potentially life-threatening complication, functional 
impairment, pain, and bleeding, and reduction in potential long-term disfigurement. 
For lesions with a low complication risk, watchful waiting is usually sufficient (112). 
The choice of treatment modality depends on patient age, growth phase of the lesion, 
IH location and size, degree of skin and tissue involvement, complication severity, 
and urgency of the intervention, possible future consequences, parental preference, 
and physician’s experience (112). Therapeutic approaches can be divided into three 
categories: local, pharmacological, or operative therapy, or combination of these. 
Since the introduction of propranolol, a non-selective β -blocker, this has been the 
first-line therapy for all IHs necessitating systemic therapy (124-126).   
 
5.2.8.1. Local treatment 
Local treatment is usually necessary for superficial cutaneous IH lesions that tend to 
ulcerate. Careful wound care is the basis and it usually consists of barrier dressing of 
the lesion to avoid trauma, secondary infection, excessive drying, and pain. Topical 
antimicrobial products and analgesics often serve as adjuvant treatment (112,127).  
 
5.2.8.2. Pharmacological treatment 
Local or systemic corticosteroids have been the first-line pharmacological treatment 
for IH, but due to their side-effects and the introduction of β-blockers for IHs, they are 
now less frequent (128,129) (Table 4). Oral propranolol is currently considered as the 
first-line systemic therapy for IHs (124,125,130,131). Current research suggests that 
propranolol effectively limits IH proliferation by causing vasoconstriction, inhibiting 
angiogenesis and nitric oxide production, and reducing renin levels, therefore limiting 
IH proliferation (56,83,132,133). Systemic β -blocker therapy is indicated for 
ulcerating IH, for impairment of vital functions, or for IH at risk for causing 
permanent disfigurement. Contraindications include cardiogenic shock or heart 
failure, sinus bradycardia, greater than first-degree AV-Block, hypotension, bronchial 
asthma, or hypersensitivity to the product (130). Propranolol has proven safe and 
efficient: a recent randomized controlled multicentre trial compared placebo to oral 
propranolol of 1 and 3 mg per kilogram/day during 3 to 6 months for 456 infants 
(126). The study found the 3-mg daily dose to be safe and efficient compared to 
placebo, with adverse events such as bradycardia, hypotension, bronchospasm, and 
hypoglycaemia being relatively infrequent. Another concern raised for propranolol’s 
use is its lipophilic nature and capacity to pass the blood-brain barrier, which may 
cause neurological side-effects such as sleeping disturbances (131). To date, no 
evidence exists on any long-lasting cognitive deficit on children having received 
propranolol therapy (134).   
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Other β-blockers have also been introduced into the management of IH. Oral atenolol 
has been proposed as an alternative for propranolol, because it is a hydrophilic 
selective β1-blocker and has less frequent adverse events; larger studies on its safety 
and efficacy are lacking, however (135-137). Topical timolol has also been suggested 
as an alternative for propranolol for superficial IH’s but it bears the risk of less 
controlled topical dosing but similar adverse effects as from other β-blockers 
(138,139).  
 
Earlier, vincristine and interferon-α were occasionally used for difficult IHs, but due 
to their neurotoxic and other difficult side-effects and the introduction of β-blockers, 
they are virtually no longer in use (140-142). Captopril, an angiotensin-converting 
enzyme inhibitor, has also recently been introduced in IH treatment, as it is able to 
inhibit the RAS (74,84). Investigators have also proposed that anti-angiogenic agents 
based on VEGF inhibition may restrict IH proliferation (143).  Rapamycin, an mTor-
inhibitor, has proven to be efficient against other vascular malformations and has also 
shown some efficacy against IH (144).  
 
 
Table 4. Summary of the most common medical therapies for infantile haemangioma, 
their indications and side-effects.  
 
Pharmacological agent Indications Side-effects 
Systemic β-blockers 
(propranolol, atenolol)  
IH necessitating 
systemic therapy 
Bradycardia, hypotension, 
hypoglycaemia, diarrhoea, 
cool extremities, sleep 
disturbances 
Topical β-blockers 
(timolol) 
Superficial IH Same as above 
Captopril IH necessitating 
systemic therapy 
Renal insufficiency 
Hypotension 
Systemic corticosteroids IH necessitating 
systemic therapy when 
β-blockers are 
contraindicated or have 
not been efficient 
HPA axis suppression, 
cushingoid features, growth 
restriction, weight gain, 
hypertension, gastric irritation, 
irritability, insomnia, immune 
suppression, cardio- and 
steroid myopathy, osteopenia, 
ocular effects 
Intralesional corticosteroids  Small, localised IH  Fat and dermal atrophy, 
hypopigmentation, same as 
with systemic corticosteroids  
Abbreviations: HPA axis: Hypopituitary adrenal cortex axis. 
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5.2.8.3. Laser therapy 
Before the introduction of β -blockers, pulsed-dye laser (PDL) therapy has been 
widely in use for superficial IHs. Nowadays, PDL mostly plays an adjuvant role in IH 
treatment (112). PDL tissue penetration of 2 mm limits its use only to the superficial 
IH component. The results and efficacy of PDL for IH are somewhat controversial 
(145-147); however, PDL may be efficient for early superficial facial IHs, for the 
superficial component of a mixed-type IH, for IHs with refractory ulceration, or for 
residual teleangiectasia (146,148). The requirement of anaesthesia limits the use of 
laser therapy, even though very small lesions can be treated under local anaesthesia 
(112).  
 
 
Figure 17. An infantile haemangioma causing visual compromise and nasal-cavity 
obstruction. A. At age 3 months before initiation of therapy. B. At age one after 
systemic corticosteroid therapy.  At age 5 years C. and at age 7 years D. after laser 
therapy and surgical correction.   
 
 
 
 
5.2.8.4. Surgical treatment  
Prior to the development of medical and laser therapy, surgery was, in addition to 
corticosteroids, one of the few IH-treatment options. Despite β-blockers, surgery still 
has a place in some IH treatment, especially for scar corrections due to tissue residue 
from an involuted IH around the age of three to six years (4,161). Surgery for IH as a?
A. B. 
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primary treatment is indicated in cases with failure or contraindication for medical 
treatment, or for complicated but focal IHs in an area favourable to surgery (4,149). 
Nonetheless, the risks of surgery, including potential blood loss, iatrogenic injury, and 
need for anaesthesia at a very young age limit its use.  
 
5.2.9.  Prognosis 
The course of IH is generally benign, and most IHs resolve without intervention and 
leave no permanent sequel. However, although one referral centre study estimated 
that approximately one-third of IH children needed some kind of intervention, recent 
prospective studies in primary health care settings estimated that only 4% of IHs 
necessitated intervention (8,9,102). Only a few investigations have measured the 
long-term morbidity and quality of life in IH children. In young IH children, head and 
neck IHs and history of intervention have been linked to elevated morbidity levels 
(150). Earlier studies in small patient cohorts report that the quality of life for older 
IH children was generally similar to that of age-standardised quality-of-life levels 
(151,152). How propranolol treatment changes the long-term outcomes for IH 
patients, remains as yet unreported.  
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5.3. Venous Malformations 
 
5.3.1. Definition 
Venous malformations result from congenital errors in the vascular morphogenesis 
involving venous structures. VMs comprise dilated disorganised venous channels that 
may invade any tissue or organ. The size, invasion and growth characteristics of VM 
are highly variable (1-3).  
 
5.3.2. Epidemiology 
VMs are the most common type of all vascular malformations, and are the second 
most common among all vascular anomalies after IH (1,4). Due to diagnostic 
challenges and the natural course of VM, its incidence and prevalence rates are 
unclear. Estimates of its incidence are 1 to 2 in 10 000 births, with a prevalence of 
approximately 1% (4,11,153,154). VMs occur approximately as often across genders 
(42). Other host-related risk factors are unknown, because the pathophysiology relies 
mostly on genetic predisposition (153).  
 
5.3.3. Pathogenesis 
Defects in vascular morphogenesis lead to the formation of a venous malformation 
(1,4). The PI3K/AKT signalling cascade, responsible for vessel stability between 
endothelial cells and supporting cell groups, plays a crucial role in the pathogenesis of 
venous malformations, and alterations or dysfunction in this cascade result in the 
formation of a VM as well as in some other vascular malformations (91,155-158). 
Vikkula and colleagues made a breakthrough discovery in finding one causative 
mutation for VM: a mutation in the TEK gene that encodes the tyrosine kinase 
receptor TIE-2 causes approximately 60% of the sporadic VMs (158,159). The TIE-2 
receptor binds angiopoietins that regulate vasculogenesis and angiogenesis: they alter 
endothelial cell proliferation, migration, and adhesion, maintain vessel stability 
between endothelial cells and their supporting cells, and maintain vascular quiescence 
(155,158,160). Thanks to these functions, the TIE-2 receptor regulates the PI3K/AKT 
signalling cascade. Mutated forms of the TIE-2 receptor activate this cascade in a 
ligand-independent manner, resulting in diminished levels of the platelet-derived 
growth factor needed to recruit mural cells to support the endothelium. This leads to 
vessel instability and discordance between endothelial cells, pericytes, and smooth 
muscle cells, and allows uncontrolled vessel sprouting. Dysfunction in this signalling 
cascade therefore contributes to VMs’ continuous dysmorphogenesis 
(91,155,157,158,161).  
 
5.3.4. Genetics 
Most VMs occur sporadically (94%), supporting the theory of a somatic mutation 
Four genetically different types of VMs exist, two of which are sporadic and two 
inherited. Sporadically occurring VM includes the classic venous malformation and 
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the rare blue rubber bleb nevus syndrome. The inherited forms of VMs comprise 
cutaneomucosal venous malformations and glomuvenous malformation (41) .  
 
The genetic cause for the classic sporadic VM has been identified as involving 
mutations in the TEK gene encoding the TIE-2 receptor in approximately 60% of 
cases, and in about 20% of cases mutations in the PIK3CA gene; these are both 
crucial players in the PI3K/AKT signalling pathway. The mutations occurring in 
sporadic cases have never been observable in inherited cases, suggesting that they are 
lethal during embryogenesis (155,156,158,160,162). Another sporadic VM type 
manifests as the blue rubber bleb nevus syndrome. It is rare and is characterised by 
several cutaneous and intestinal VM lesions, often leading to chronic anemia due to 
bleeding (41,163). For the blue rubber bleb nevus syndrome, a specific somatic TIE2 
mutation form has recently been considered causative (164).  
 
Inherited forms of VMs account only for approximately 1 to 5% of all VMs. They 
include the autosomal dominantly inherited cutaneomucosal venous malformations 
caused by gain-of-function mutations in TIE2, distinct from the mutation that is 
observable in the sporadic form (156,160,161). Another type of an inherited VM is 
called a glomuvenous malformation: this also follows an autosomal dominant 
inheritance pattern. Glomuvenous malformations are clinically quite similar to 
sporadic VM, but they have some peculiar features: they appear as pink or bluish 
lesions, mostly superficially and often elevated on the skin (165). Glomuvenous 
malformations result from mutations in the glomulin gene that affects angiogenesis 
and smooth-muscle cell development (166-168).  
 
Understanding of genetic mutations that alter the function of the PI3K/AKT signalling 
cascade at various stages has led to dramatically increased understanding of the 
pathophysiology of VM types, and for VMs has facilitated the development of 
targeted medical therapies (169).  
 
5.3.5.  Histopathology 
Venous malformations appear as dilated or thickened dysplastic vascular channels 
lined with mature endothelial cells with no internal elastic lamina and only a partial 
smooth muscle cell lining (1,92). Erythrocytes are observable in the vascular spaces, 
and due to the VM-related local intravascular coagulopathy, luminal thrombi and 
calcified phlebolitis are often present. To differentiate VMs from LMs, many fewer 
intraluminal erythrocytes occur in LMs, as LMs contain mostly lymphatic fluid. 
AVMs, on the other hand, can be distinguished from VMs thanks to AVMs’ 
characteristic dilated arterial structures, thick walled veins, and disturbed vessel 
architecture (92,170). 
 
Immunohistochemical staining is in all vascular malformations quite similar. Unlike 
the IH, vascular malformations stain negative with GLUT-1 marker (92). All vascular 
malformations seem to stain positive with nerve-tissue-avid S-100 stain (171). VMs 
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and LMs may, however, microscopically resemble each other. For the distinction, D2-
40 antibody stains positive in LMs but negative in VMs (172).   
 
5.3.6.  Clinical presentations   
Venous malformations appear as variably-sized abnormal veins that may invade any 
tissue or organ. VMs may appear as either superficial or deep and can be either 
diffuse or localised (Figure 18). Some patients suffer from multiple lesions. VMs are 
typically soft, non-pulsating, bluish lesions that often accentuate and become apparent 
in a dependant position, during the Valsalva manoeuvre, or at physical exercise. Due 
to the slow-flow nature, coagulation and painful phlebolitis may occur.   
 
 
Figure 18. A. A venous malformation (VM) of the lip. B. A VM in the ear lobe. 
 
 
 
5.3.6.1. Clinical course  
VMs are present but often not visible at birth, progress slowly commensurate with 
physiological growth, and never regress. Trauma, partial resection, puberty and 
pregnancy often accelerate VM growth due to the increase in blood volume and to 
probable hormonal factors (1,4,92,173,174).  
 
5.3.6.2. VM localisation and tissue involvement 
Approximately 40% of the VMs reside in the head and neck, most commonly in the 
cheek, lip, or oral cavity. Extremity VMs account for 40% and trunk VMs for 20% of 
all VM lesions. VMs vary in size and tissue infiltration, potentially invading any 
tissue plane, joint, or the viscera (Figure 19) (173,174).   
?
A.  B.  
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Figure 19. A. A venous malformation behind the tonsil that extends diffusely to the 
neck, manifesting as bluish skin in the neck, B. 
 
 
 
 
5.3.6.3. VM symptoms and complications 
VM symptoms are highly dependent on lesion size and location. Most typical VM 
symptoms include pain and swelling due to position or physical activity, aesthetical 
discomfort, functional impairment, local compression of neural, capsular, or fascial 
structures resulting in pain, and restricted joint or muscle movement (4,173). Due to 
the slow-flow nature and stasis in the VM, chronic localized intravascular 
coagulopathy is often present, leading to thrombosis but also to bleedings due to low 
fibrinogen levels. This coagulopathy predisposes patients to severe thromboembolic 
complications, such as pulmonary embolism, but also to bleedings due to 
consumption coagulopathy (170,173). VMs infiltrating the orbit often cause visual 
impairment, and VMs near the airways may lead to airway obstruction (4).  
 
5.3.6.4. VM-associated syndromes  
Some VMs are related to syndromes that usually aggravate the clinical presentation 
(5). Klippel and Trenaunay described in 1900 a syndrome with a distorted and 
hypertrophic lower limb affected by a diffuse VM, combined with a capillary-, or a 
lymphatic component, or both (4). Klippel-Trenaunay syndrome manifests mostly 
unilaterally in one limb, although bilateral cases do occur. Symptoms and morbidity 
of this syndrome involve cutaneous staining due to the capillary component, 
lymphedema and cellulitis due to the LM, and venous structural abnormalities 
affecting both the superficial and deep venous system, leading to valvular 
incompetence, dilations, and venous stasis. These may result in ulceration, 
coagulopathy, deep venous thrombosis, and potentially to pulmonary embolism 
(4,175-177). Most cases occur sporadically; gene mutations in pro-angiogenic factors 
or proteins in the PI3K/AKT signalling pathway have been proposed as causative 
(41).  
 
A. B. 
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In addition to Klippel-Trenaynay, there occurs a set of other syndromes involving 
VMs. Inherited forms of VMs have already been discussed. Mafucci’s syndromes 
comprise venous and lymphatic malformations accompanied by multiple 
enchondromas, exostoses, and spindle cell haemangioendotheliomas. Proteus 
syndrome involves mixed vascular malformations with skin disorders, overgrowth, 
atypical bone development, and high tumour incidence. Gorham-Stout syndrome 
associates with venous or lymphatic malformations or both, and results in bone loss 
replaced with fibrous tissues. Bockenheimer syndrome is a rare, congenital, 
progressive diffuse phlebectasia affecting most commonly the upper limbs (177-179).   
 
5.3.7. Diagnostic methods 
The diagnosis of venous malformations is based on typical clinical course and 
presentation, imaging studies, and on histopathology, when diagnosis is uncertain 
(180-182). Correct diagnosis is often difficult: based on a large vascular-anomaly-
centre study, the referral diagnosis for a VM patient was correct only in 31% of the 
cases, emphasising the importance of an interdisciplinary vascular-anomaly team. 
Distinguishing VMs from AVMs and other vascular malformations as well as from 
vascular tumours and malignant lesions is crucial. Medical photography serves as a 
useful tool in the follow-up (15,42,182).  
 
Ultrasonography (US) usually serves as first-line imaging for VMs, as it is widely 
available, non-invasive, devoid of ionizing radiation, and applicable without general 
anaesthesia. In addition, it plays an assistive role in image-guided biopsy or 
intervention (180,183). US serves for relatively superficial and confined lesions, but 
with US, deeper and more diffuse lesions are difficult to completely visualize with US 
(154). VMs usually appear in US as heterogenous and hypoechoic. Their vascular 
spaces may contain phlebolitis, which is pathognomonic for VMs (173,184). When 
the diagnostic probability for a vascular malformation is high, a US examination can 
usually clarify the flow of the lesions, in order to distinguish high-flow lesions 
(AVMs) from low-flow lesions (VM and LM) thanks to Doppler analysis (184). In 
cases with any diagnostic doubt as to lesions other than a vascular malformation, 
other imaging modalities or biopsies are necessary (180,185).  
 
MRI has become the first-line imaging choice for VMs when US and clinical 
examination are insufficient (Figure 20). The advantages of MRI include a non-
invasive and non-radiating evaluation of the whole lesion architecture and adjacent 
structures as well as excellent soft-tissue- and flow assessment. MRI is usually 
applied when planning an intervention. The disadvantages of MRI are the necessity of 
anaesthesia in paediatric patients, higher cost, and lower availability than with US 
(173,181,186,187). On T1-weighted images, VMs appear as iso- or hypointense, and 
occasionally hyperintense when containing fat. On T2-weighted images, VMs show 
high signal intensity. Gadolinium in fat-saturated sequences reveals the lesion’s 
vascularity and thus distinguishes it from perilesional fat (121,173,181,187-190). On 
MRI, VMs differ from AVMs in T1 and T2 signal intensities, and in the amount of 
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soft tissue component, scarce in AVMs (121,174,186,187,191). Dynamic contrast-
enhanced MR-angio- or venographic techniques help in distinguishing between high 
and low-flow lesions (192-195). The distinction between VM and LM is usually clear, 
as the latter is not enhanced with gadolinium, although microcystic LMs may, in 
MRI, mimic VMs (121,174,187,196). MRI combined with dynamic techniques 
provides 100% sensitivity and 95% diagnostic specificity (192).   
 
 
Figure 20. A typical venous malfromation with phlebolitis in T1 sequence: A. in T2 
fat-saturated image, B. and D., and C. coronal T1 image with gadolinium.  
 
 
 
 
Phlebography, usually performed under fluoroscopy as a direct percutaneous puncture 
of the VM and then contrast injection, serves for assessing VM morphology and flow 
characteristics. It is often used prior to sclerotherapy (173,181).  
?
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When any uncertainty exists as to VM diagnosis, a biopsy and histopathological 
examination is necessary to rule out malignancies. Unlike malignant lesions, VMs 
exhibit flat, mature endothelial cells. To distinguish VMs from vascular tumours and 
other vascular malformations requires immunohistochemical staining (1,92).  
 
5.3.8.  Treatment 
Treatment of VMs constitutes a challenge. As in treating any non-malignant disease, 
careful assessment of treatment indications and of possible treatment-related 
complication risks will prove crucial. When the VM causes haemorrhage or severe 
coagulopathy, or threatens vital structures or functions, intervention is necessary. 
Relative indications for intervention include pain, discomfort, and functional or 
aesthetic impairment. The decision on intervention for VMs and the treatment 
strategy should be tailored to each patient individually in an interdisciplinary setting 
(173,197).  
 
5.3.8.1. Conservative treatment 
A number of VM patients can be conservatively managed after proper diagnostics and 
patient information in case the VM symptoms are bearable (4,173,174). The first 
conservative treatment option is a compressive garment or stockings, especially for 
extremity VMs. These garments aim to limit tissue swelling and pain, to slow the 
progression of the VM, to alleviate the localized intravascular coagulopathy, and to 
reduce the risk for thrombosis. When marked localized intravascular coagulopathy 
occurs with elevated D-dimer and low fibrinogen levels, anticoagulation is indicated 
to reduce the risk for thrombosis and thromboembolic complications as well as to 
alleviate the pain due to existing thrombosis (170,173,188,197,198). 
 
5.3.8.2. Surgical treatment 
Before the development of modern interventional radiology, surgery was virtually the 
only intervention modality for VMs (4). Even though interventional radiological 
techniques have gained ground, surgery is still an appropriate treatment modality for 
some lesions. Focal, confined VMs, for which complete excision is possible without 
loss of significant adjacent tissues, are suitable for surgery (173,197,199). Nowadays, 
surgery serves mostly as an adjuvant treatment after sclerotherapy or laser therapy for 
large VMs in which a sufficient number of venous channels must be closed with 
intravascular techniques before tissue excision (4,199). The disadvantage of surgery is 
the loss of large tissue areas and, when only partial resection is achieved, re-growth of 
the VM (173,182,197).  
 
5.3.8.3. Percutaneous sclerotherapy  
Percutaneous sclerotherapy is considered as the first-line therapy for most VMs. The 
goal of sclerotherapy is to damage endothelial cells within the VM, resulting in 
scarring and closure of the vascular channels and eventually in shrinkage of the VM. 
The aim of sclerotherapy is symptom relief. For large lesions, sclerotherapy also 
targets control of coagulopathy and aims to facilitate further surgery by reducing the 
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volume of open vascular spaces (4,154,173,174,197). Successful and complication-
free sclerotherapy is dependent on the sclerosant agent, patient preparation, and the 
technical expertise of the interventional radiologist (197,200,201).  
 
Sclerosing agents  
The choice of sclerosing agents depends on VM location and morphology. Sclerosing 
agents differ in toxicity, viscosity, and complication risks. Currently many agents, 
either alone or in combination, can achieve the best possible result with an acceptable 
risk profile (Table 5). Due to the heterogenous study settings, however, no clear 
evidence yet exists as to the superiority of any one sclerosant (202,203). To treat VMs 
in confined areas, sclerosants causing the least oedema, ones such as bleomycin, may 
be wise choices. Sclerosing agents are listed in Table 5.  
 
 
Table 5. Summary of sclerosing agents (182,202-210).   
 
Sclerosing agent Advantages Disadvantages 
Ethanol-based sclerosants   
Ethanol (95%) Effective 
Recanalization rare 
Inexpensive 
Potentially very toxic 
Local complications: tissue 
necrosis, nerve injuries 
Systemic complications: 
haemoglobinuria, pulmonary 
hypertension and embolism, 
cardiac collapse 
Ethanolamine oleate Viscose, low vessel 
penetration  
Safer than ethanol 
Systemic complications: 
haemolysis, renal insufficiency, 
hepatotoxicity 
Ethanol Gel Viscose, low vessel 
penetration  
Safer than ethanol 
Local tissue injuries 
Fewer systemic side-effects than 
with ethanol 
Detergent sclerosants  
Sodium tetradecyl sulphate 
(STS) 3% 
Detergent, foam 
allows good 
endothelial contact 
 
More recanalization  
Local complications possible 
Systemic complications: 
urticaria, anaphylaxis, 
haematuria 
Polidocanol Detergent  
Painless 
In different 
concentrations  
Local complications possible 
Systemic complications: 
Haemolysis, haemoglobinuria, 
cardiac arrest (rare) 
Sodium morrhuate See STS Less effective than STS 
Others   
Bleomycin,  
Pingyamycin 
Anti-cancerous 
antibiotic 
Minimal swelling 
Transient fever, skin necrosis, 
tissue atrophy, potential 
pulmonary fibrosis 
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Sclerotherapy procedure 
Monitoring the patient’s coagulation status is advisable. Sclerotherapy is mainly 
executed under general anaesthesia; only small and superficial VMs, along with 
sufficient patient co-operation, are suitable for treatment under local anaesthesia 
(182). The patient should be informed of the course and possible complications of 
sclerotherapy. 
 
Prior to injection of the sclerosant, assessment of the VM morphology and drainage is 
necessary. This is usually achieved by phlebography or by iodinated contrast injection 
under US-guided fluoroscopy (182). If the venous drainage flows into large or critical 
veins, mechanical compression is necessary to prevent any systemic leak. Currently, 
the draining technique is widely used: several needles are placed into the VM, and 
after confirming their entry into the venous space by retrograde blood flow, the 
sclerosing agent is injected through one needle, while other needles permit the 
sclerosant outflow. This technique prevents VM’s overfill, any rise in intraluminal 
pressure, and any potential sclerosant leakage (211).  
 
Patients are monitored after sclerotherapy depending on VM extent and location: 
patients with small lesions can be discharged after two to three hours of monitoring, 
whereas patients with large VMs located close to critical structures or with any 
coagulation disturbance should be hospitalized until stable (182,201,212). After the 
procedure, a compressive garment helps to reduce swelling and supports closure of 
the venous channels. When extensive oedema is expected, per oral corticosteroid 
administration is advisable for 3 to 5 days. Regular analgesics serve for pain relief. 
Follow-up and consecutive therapies are programmed for each patient individually 
depending on response to the therapy (182,201,209,212).  
 
Sclerotherapy outcome 
Sclerotherapy outcome depends on patient satisfaction, symptom relief, and clinical 
evaluation. Objective and standardized outcome- and complication-measurements 
methods for sclerotherapy are lacking, mostly due to the heterogeneity of VMs, 
differing practices between vascular-anomaly centres, and variable study settings. 
Recent review studies could find no superiority of any sclerosants in regards to 
sclerotherapy outcome; in one review, the complete-response rate (regression of at 
least 80% of the vascular malformation) ranged from 33% to 76%, and overall 
response (subjective symptom relief or reduction in VM volume) rate was 71% to 
100%. Another review study stated that among ethanol, polidocanol, ethanolamine 
oleate, and STS, all but STS exceeded a total efficacy rate of 90%. However, follow-
up periods in the studies included in the reviews ranged from 0 to 120 months, mostly 
being between 3 and 20 months, rendering evaluation of long-term efficacy difficult. 
Additionally, the academic quality of these studies was evaluated as being low or very 
low (202,203). Based on the current literature, solid and objective evaluation of 
sclerotherapy efficiency and of various sclerosants is therefore difficult. 
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Sclerotherapy complications 
Currently no standardized consensus exists on classifying sclerotherapy 
complications. However, because sclerotherapy has largely replaced surgery in VM 
treatment, systematic assessment of complications is necessary. Most studies divide 
complications into local and systemic, or minor and major complications, leaving the 
interpretation subjective (203). The Society of Interventional Radiology has 
introduced a classification for all radiological procedures, but this is only in part 
applicable in sclerotherapy, as it divides complications into minor and major 
complications, and therefore remains relatively subjective (213). An alternative 
classification for sclerotherapy could be the Clavien-Dindo classification of 
complications, widely applied and standardized in surgery (214-216). It divides 
complications into five categories dependent on the procedures needed to treat the 
complication, which makes it an objective grading system. The weakness of the 
Clavien-Dindo classification is, however, that complications leaving permanent nerve 
injuries or pain, ones non-reparable by an intervention, receive little attention.  
 
The most common sclerotherapy complications include various levels of skin damage 
in approximately 10% of the cases. Other relatively common complications are nerve 
injuries, muscle fibrosis, post-procedural infections, and transient haemoglobinuria. 
Less frequent but severe complications include renal damage, severe bleedings, 
pulmonary embolism, pulmonary hypertension and oedema, and cardiac collapse. 
Ethanol-usage reportedly produces the highest complication rates (201,203,204). 
Overall complication rates show a dramatic range of 0 to 61%, depending on the 
study and its definition of a treatment complication (200,203,206,212,217-222).   
 
5.3.8.4. Laser therapy 
Endovascular laser therapy, mainly by diode or YAG laser, has during recent years 
gained ground in treating VMs. Such therapy is suitable for selected lesions, and it 
can be performed as a staged procedure, as sclerotherapy. Current research data on 
endovascular laser therapy for VMs is relatively scarce; however, the existing 
outcome and complication results are promising (197,223-226). A recent study from 
Simon and colleagues found endovascular laser therapy to provide good symptom 
relief for 32 patients with aerodigestive tract VMs suffering from sleep apnea: they 
showed significant reduction in dysphagia, in sleepiness score, and in apnea-
hypopnea index, and the treatment diminished patients’ need for positive-air-pressure 
equipment (227).  
 
5.3.8.5. Pharmacological management 
Rapamycin, an mTor inhibitor, is a recently introduced treatment option for VMs 
resistant to other therapies. It blocks the VM-causative PI3K/AKT-signalling 
pathway, and limits lesion progression. Future clinical use and research will reveal the 
role for this drug in treatment strategy for VMs (169).  
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5.3.9.  Prognosis 
Venous malformation is a chronic condition. The aim of any treatment is to limit the 
symptoms and morbidity, and to improve the quality of life. Sclerotherapy has been 
efficient in improvement of the quality of life for VM patients after a follow-up 
period of one year (222,228); yet, long-term outcomes and quality of life 
measurements as well as prospective randomized studies are lacking, mostly due to 
the rarity of this condition plus many heterogenous treatment protocols and study 
settings (202,203). Despite most therapies, VMs tend to gradually recur, emphasizing 
the necessity of an interdisciplinary approach in follow-up and treatment planning, the 
main goal being efficient symptom relief with acceptable side-effects, no matter the 
treatment modality (4).  
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6. Aims of the study 
 
This study concentrates on infantile haemangioma and venous malformation. It aims 
to elucidate the risk factors for and inheritance model of IH, and to critically evaluate 
the safety of sclerotherapy treatment for VMs. The objective is to answer the 
following questions: 
 
1. What are the risk factors for complicated, morbidity-inducing infantile 
haemangiomas? Do perinatal risk factors for IH differ in our study population 
from those reported in earlier studies in other populations? 
 
2. What are the characteristics of familial infantile haemangiomas? What 
inheritance patterns can be identified for familial infantile haemangiomas? 
 
3. What are the sclerotherapy complications for head and neck venous 
malformations? How common are the complications? How severe are the 
complications according to a standardized classification? What VM-related 
and technical characteristics affect the complication risk? 
 
4. What are the sclerotherapy complications for trunk and extremities venous 
malformations? How common are the complications? How severe are the 
complications according to a standardized classification? What VM-related 
and technical characteristics affect the complication risk? 
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7. Patients and Methods 
 
7.1. Ethical considerations 
 
All study protocols were approved by the Helsinki University Hospital’s ethics 
committee. The study protocols followed good clinical practice and conformed to the 
Declaration of Helsinki. All patients and their caregivers taking part in infantile 
haemangioma studies signed an informed consent. Our VM patient data consisted of 
retrospective chart reviews.  
 
 
7.2. Helsinki University Hospital district 
 
Helsinki University Hospital (HUH) is a referral centre serving 1.5 million inhabitants 
in southern Finland. It maintains a comprehensive electronic hospital record covering 
all disciplines, excluding primary health care records. All patients in these studies 
have been treated and followed in HUH. Since 2002, an interdisciplinary vascular 
anomaly team of HUH has coordinated the diagnostics, treatment, and follow-up of 
patients with extracranial vascular anomalies. It also receives referrals concerning 
vascular anomalies from other hospital districts in Finland. The interdisciplinary team 
consists of paediatric, plastic, and maxillofacial surgeons, otorhinolaryngologists, 
dermatologists, ophtalmologists, pathologists, and radiologists.  
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7.3. Risk factors for and inheritance of infantile 
haemangioma  
 
We identified from electronic hospital records all patients who had visited HUH’s 
paediatric vascular anomaly clinic between 2004 and 2007 with diagnosis D18.0 
(haemangioma), or Q82.5 (birthmark), based on the 10th International Classification 
of Diagnoses (ICD-10). For the 263 patients who matched these criteria, we examined 
their electronic hospital records.  Based on patients’ clinical characteristics, typical 
clinical course during follow-up, photography, and imaging studies, we found 185 
patients with infantile haemangioma. The remaining 78 patients either had a 
congenital haemangioma (7), undefined haemangioma (17), or other vascular 
anomaly or birthmark (54), and they were excluded from the study. For the 185 
children with IH, we noted gender, ethnic background, current age, and age at the first 
and last visit to HUH. We recorded all IH-related complications and interventions.  
 
We registered the number of IH lesions, location, and subtype, and classified each 
IH’s morphological subtype as focal, multifocal (≥10), segmental, or indeterminate 
based on the lesion with most clinical relevance. To investigate IH patients’ 
gestational and perinatal factors from hospital records, we collected all information 
available on gestational age, multiple gestations, birth weight, first-minute Apgar 
score, type of delivery, any possible other diseases, positive family history of IH, plus 
maternal age, in vitro fertilization therapy (IVF), gestational diabetes mellitus (GDM), 
preeclampsia (PE), placenta praevia, chorionic villus sampling (CVS), other maternal 
diseases, mothers’ medications, and cigarette smoking during pregnancy. Only part of 
these data appeared in IH children’s records, and we were not allowed to access 
mothers’ hospital records.  
 
Patient questionnaire and interview 
We contacted patients with a confirmed IH diagnosis and their caregivers with a 
questionnaire to acquire information on perinatal, maternal, and gestational 
information, the child’s current diseases, family history of an IH, and other treatments 
for IH occurring outside of HUH (Article II, Appendix 1). We requested data on these 
patients’ current subjective IH-induced long-term discomfort on the visual analogue 
scale (VAS) ranging from 1 (no discomfort) to 10 (very significant discomfort). To 
achieve a maximal response rate, the questionnaire was sent three times if necessary.  
 
We re-contacted by phone those families who reported a positive IH family history 
and permitted re-contacting to record the family pedigrees. The course of IH in 
affected family members, its location, and the number of lesions for all the affected 
family members were confirmed. We also asked families about any other inherited 
diseases in the family. The birthplaces of the grandparents of the IH-affected family 
side were recorded in order to identify regional clustering and possible founder effect. 
If the grandparents’ birthplace was unknown, the parents’ birthplaces were registered. 
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Analysis of the inheritance patterns and geographic distribution of IH families was 
based on these data.  
 
Reference data 
The diagnostic challenges regarding vascular birthmarks and the misuse of the term 
“haemangioma” disallowed our sending the questionnaire to a randomly selected 
control group, as this would have yielded most likely many false-positive but also 
false-negative IH cases (5,15,42,112). Therefore, to analyse the perinatal, gestational, 
and maternal risk factors for IH, we acquired our hospital district’s pre- and perinatal 
statistics on live childbirths within the same catchment area, 2004-2007, from the 
Finnish National Institute for Health and Welfare (THL). These data served as our 
reference material, as they represent well the average newborns in our hospital 
district; however, due to differing sources of data for the IH patients and reference 
individuals, we regarded this also as a limitation.  The THL annually receives 
information on all childbirths as well as their perinatal events, maternal health, and 
demographic characteristics from maternity and obstetrics clinics, clinics that all 
follow the national guidelines for the diagnostics of gestational diseases. The THL 
maintains the Finnish Medical Birth Register (FMBR). After data linkages to our 
Central Population Register for live births and Cause-of-Death Register for stillbirths 
and infant deaths, the FMBR covers all newborns in Finland.  
 
Statistics 
Only patients with a confirmed IH diagnosis underwent statistical analysis. For 
analysis regarding gender, number of IH lesions, location, complications, and 
interventions, we included all patients for whom the information was available.  
 
Patients with one or more IH-affected relatives were considered to be familial cases. 
We undertook the statistical analysis by comparing all familial IH cases to sporadic 
cases, and those familial IH cases with an affected first-degree relative to sporadic 
cases regarding IH, perinatal, and long-term morbidity data, based on all available 
data acquired from the patient records and questionnaire.  
 
To analyse and to compare the perinatal, gestational, and maternal factors in our IH 
cohort to FMBR data of the same catchment area and time period, we included only 
patients who had responded to the questionnaire in order to avoid any positive 
reporting bias on perinatal complications in child’s hospital records. This bias was 
due to the fact that we only had access to the child’s records but not the mother’s: it 
was therefore more likely that in cases with any gestational or perinatal complication, 
this was usually reported in the child’s records, whereas an uncomplicated perinatal 
period was often left unreported. We also show the rates based on all available 
information. 
 
For continuous variables, comparison between two independent groups was by the 
Mann-Whitney U-test. For categorical variables, we used the Chi-Square test, or, 
?? ??
when Chi-Square test preconditions were not met, Fisher’s exact test. For bivariate 
analysis, Mantel-Haenszel and heterogeneity tests were applied. All analyses were 
performed with NCSS8 Statistical Software. 
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7.4. Sclerotherpy for venous malformations 
 
We identified patients treated with sclerotherapy for either head and neck, or trunk 
and extremity VMs between 1 January 2007 and 31 August 2013 from the Hospital’s 
electronic radiology information system. We based VM diagnosis on clinical 
evaluation, MRI, and ultrasonography imaging according to the criteria of the ISSVA 
classification (18). We recorded VM patients’ demographic details, the VM location 
and tissue involvement, possible previous surgery, number of sclerotherapy sessions, 
sclerosants, administration of perioperative corticosteroid for head and neck VMs, 
alterations in coagulation factors for trunk and extremity VMs, other treatment 
modalities used, follow-up, and sclerotherapy complications. For facial VMs, we 
recorded location further into subgroups of lower face, mid-face, upper face, neck, 
oral cavity, orbit, or a combination of these. The tissues affected by the VM were 
classified as subcutaneous, submucosal, intramuscular, intraosseal, intra- or 
retroperitoneal, intra-articular, or a combination of these.   
 
Sclerotherapy procedure 
Indications for sclerotherapy included pain, functional impairment, or aesthetic 
impairment, compromise of vital structures, or coagulation disturbance. The 
interdisciplinary team assessed the treatment indication individually for each VM 
patient. A trained interventional radiologist performed all sclerotherapies. 
 
During the sclerotherapy procedure, access to the VM lesion was obtained by 
cannulating the VM with one or several needles under ultrasound guidance. 
Retrograde blood flow confirmed the intravenous access. Then, fluoroscopy by 
iodinated contrast injection served to assess VM architecture and draining veins. If the 
venous drainage circulated through critical venous routes or was rapid, the draining 
veins were either mechanically blocked or compressed. For most sclerotherapies, we 
used this same draining technique to prevent overfill of the VM, and systemic leakage 
of the sclerosant, but also to ensure the draining of the whole lesion to achieve 
sufficient response. In case of small, superficial VMs with good patient co-operation, 
local anaesthesia and conscious sedation was sufficient. For larger and deeper VMs in 
delicate or painful areas, or for ones potentially threatening the airways or other vital 
structures, sclerotherapy was executed under general anaesthesia. 
 
For all head and neck, and for most trunk and extremity VMs, we used only 
percutaneous sclerotherapy. In 4.2% of procedures for trunk and extremity VMs, we 
used adjuvant endovascular techniques to obtain a sufficient response. The indication 
for adjuvant therapies involved mostly large, demanding VMs, in which sole 
sclerotherapy was assessed as insufficient. These regimes included n-butyl-2-
cyanoacrylate glue for closing very large venous spaces, coils for closing the VM’s 
draining veins, particles for embolizing VM-feeding arteries, or an intravascular laser 
for very large VMs.  
?? ??
 
Sclerosants 
We used mainly foaming detergent sclerosants  (3% sodium tetradecyl sulfate (STS) 
or polidocanol 5-30 mg/ml) and rarely bleomycin (1 mg/ml), 95% ethanol, 
doxicyclin, or a combination of sclerosants, the first-line choice being mainly STS. 
For small VM lesions, polidocanol was often chosen, as different concentrations are 
available. For VMs in confined locations at risk for undesired oedema and potential 
nerve compression, we preferred bleomycin. Ethanol was rarely used, and it mainly 
served in combination with other sclerosants for extensive lesions, responding poorly 
to other sclerosants.  
 
Periprocedural treatment 
For patients with large VMs, we monitored the blood D-dimer and fibrinogen prior to 
the procedure and consulted a haematologist when necessary. In cases of an extensive 
trunk and extremity lesion, we monitored urine haemoglobin and volume. Patients 
with large VMs or at high complication risk remained in hospital until stable. Those 
patients at low complication risk stayed only for 2 to 3 hours in the hospital after the 
treatment. For VMs at risk for extensive oedema, or for VMs in confined locations, 
perioperative corticosteroid was administered. To further inhibit post-procedural 
tissue swelling and to favour closure of the vascular channels, we recommended the 
patient to wear a compressive garment if such was applicable. All patients were 
advised to contact the hospital in case of any complications.  
 
Consecutive therapies and follow-up 
Small VM lesions resolved mostly with only one sclerotherapy session. For extensive 
VMs, we scheduled several sclerotherapies in series, as they were anticipated to 
require multiple sessions. Most patients were clinically monitored for approximately 3 
to 6 months after sclerotherapy. If the treatment response was sufficient at the follow-
up, the patients were advised to contact our clinic in case of recurrence or symptoms. 
If the symptoms persisted despite repeated sclerotherapies, the interdisciplinary team 
evaluated the possibilities of other treatment modalities. For example, even after their 
venous channels had been closed with sclerotherapy, some large lesions required de-
bulking surgery. Passive follow-up time was recorded from the last sclerotherapy to 
the study date. Because of the lack of any other hospitals providing treatment for 
vascular anomalies in our hospital district, it was very unlikely that a VM patient 
would have sought treatment from any other institution. 
 
Complication assessment 
With all available data from hospital records concerning the sclerotherapy 
complications and management of the complications, we assessed all sclerotherapy 
complications retrospectively in our interdisciplinary team. Based on the team’s 
consensus, the grade for each complication was set according to the Clavien-Dindo 
classification (Table 6) (214-216) .  
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Table 6. Clavien-Dindo classification of complications (215). Reprinted with the 
permission of Wolter Kluwer Health from Dindo D. et al. “Classification of surgical 
complications: a new proposal with evaluation in a cohort of 6336 patients and results 
of a survey.” Ann Surg. 2004 Aug; 240(2):205-13. 
 
Grade Definition 
Grade I Any deviation from the normal postoperative course without the need for 
pharmacological treatment or surgical, endoscopic, and radiological 
interventions. Allowed therapeutic regimens are: drugs as antiemetics, 
antipyretics, analgetics, diuretics, electrolytes, and physiotherapy. This 
grade also includes wound infections opened at the bedside.  
Grade II Requiring pharmacological treatment with drugs other than such allowed 
for grade I complications. Blood transfusions and total parenteral 
nutrition are also included. 
Grade III Requiring surgical, endoscopic, or radiological intervention 
   IIIa Intervention not under general anaesthesia 
   IIIb Intervention under general anaesthesia 
Grade IV Life-threatening complication (CNS complications)* requiring IC/ICU 
management 
   IVa Single-organ dysfunction (including dialysis) 
   IVb Multi-organ dysfunction 
V Death of a patient 
Suffix ‘d’ If the patient suffers from a complication at the time of discharge, the 
suffix “d” (for disability) is added to the respective grade of 
complication. This label indicates the need for a follow-up to fully 
evaluate the complication.  
* Brain haemorrhage, ischemic stroke, subarachnoidal bleeding, but excluding 
transient ischemic attacks. Abbreviations: CNS: central nervous system; IC: intensive 
care; ICU: intensive care unit. 
 
 
Statistics 
Analyses for variables predicting complications were executed with Chi-Square test, 
or when the preconditions were not met, with Fisher’s exact test. Mann-Whitney’s 
test served for analysis of continuous variables. A P-value of <0.05 was considered 
statistically significant. Microsoft Office Excel 2007 and NCSS8 Statistical Software 
served for data analysis. 
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8. Results 
 
8.1. Risk factors for and inheritance of infantile 
haemangioma 
 
We identified initially 263 patients, of whom 185 had a true infantile haemangioma 
and were included in the study. Of these patients, 134 (72%) were female, and 51 
(28%) were male. Most patients originated from Finland; 9% had both parents and 
8% one parent originating outside of Finland. These patients visited our clinic for the 
first time on average at the age of 12 months (median 7 months, range 1-158 months), 
and were followed until the age of 5 years (median 60 months, range 4-158 months). 
 
Patient questionnaire 
Of the 185 patients and their families, 136 (74%) responded to the questionnaire. We 
found no difference in ethnic background, nor in perinatal, maternal, nor gestational 
profile between those whose caregivers responded and those failing to respond. The 
IH patients were on average 10 years old (range 7-20 years) at the time the 
questionnaires went out.  
 
IH number, location, and subtype 
In total we counted 332 IH lesions (median 1; range 1-30 IHs). Of these 185 children, 
50 (27%) had multiple (>1) IHs, and these children were significantly more often 
female (p=0.032, OR 2.45, 95% CI 1.06-5.67). Head and neck localisation occurred 
most commonly: IH located in the face in 42% of the children, in other parts of the 
head in 14%, in the neck in 11%, and in the trunk in 44%. The IH lesion located in the 
upper limb in 12% and in the lower limb in 14%. The IH subtype was focal in 75%, 
segmental in 4%, multifocal in 1%, and indeterminate in 20%. 
 
Risk factors for IH localization and subtype 
We observed that chorionic villus sampling had taken place significantly more 
frequently during the gestation of those children with an IH in the upper limb 
compared to other locations (p=0.036, OR 4.8, 95% CI 1.18-19.50). History of 
gestational diabetes mellitus did somewhat predict a facial IH location: of the 13 
children undergoing GDM, 9 (69%) manifested a facial IH; this difference was, 
however, statistically non-significant (p=0.082, OR 3.05, 95% CI 0.90-10.35). We 
observed no other associations between perinatal, gestational, nor maternal factors 
with IH location or subtype.  
 
IH complications and intervention 
Complications of IH affected, among the 185 patients, 65 (35%). The most common 
complications were ulceration and visual axis compromise. Intervention was 
necessary for 68 (37%). The most common interventions were pulsed-dye laser and 
?? ??
surgery, because these children were born prior to the introduction of β -blocker 
therapy (Table 7). 
 
Table 7. Summary of IH complications and interventions for the 185 IH children in 
our cohort. Patients may have had more than one complication. Re-printed and 
modified from the original article with the permission of John Wiley & Sons Ltd. 
 
IH complications N (%) 
Ulceration 48 (26) 
Visual axis compromise 18 (10) 
Airway obstruction 4   (2) 
Cardiac compromise 2   (1) 
Auricular canal obstruction 1   (0.5) 
Interventions for IH  
Pulsed-dye laser 36 (19) 
Surgical scar correction 25 (14) 
Surgical removal 20 (11) 
Eye patching 13 (7) 
Systemic corticosteroid 12 (6) 
Local corticosteroid injections 5   (3) 
Other interventions (embolization, radiofrequency ablation) 8   (4) 
 
 
Risk factors for IH complications, interventions, and long-term discomfort 
Ulceration occurred significantly more often in preterm IH children than in term 
infants (p=0.041, OR 2.29, 95% CI 1.02-5.14). Complications, interventions, and 
long-term discomfort rates were unaffected by any other perinatal, gestational, or 
maternal factor. We observed elevated complication, intervention, and discomfort 
rates in IH children with facial and neck locations, and in IHs of segmental and 
indeterminate subtypes. Focal and truncal IHs were at lower risk for adverse events 
(Tables 8 and 9). The reported average long-term discomfort rate in the whole cohort 
was 2.31 on the VAS scale from 1 to 10, and was mostly due to aesthetic or 
psychosocial concerns. 
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Table 8. Summary of characteristics of infantile haemangioma (IH) that significantly 
either elevate (↑) or reduce (↓) the risk for any IH complication, IH ulceration, or 
intervention. Re-printed and modified from the original article with the permission of 
John Wiley & Sons Ltd. 
 
IH / patient 
characteristics 
Elevated (↑) 
or reduced (↓) 
risk for 
 
% (N) P value OR (95% CI) 
Perinatal       
Preterm birth Ulceration  ↑ 41 (13/32) 0.041 2.29 (1.02-5.14) 
IH subtype      
Segmental  Complication  ↑ 100 (7/7) <0.001 45.9 (2.55-824) 
 Ulceration  ↑ 57 (4/7) 0.037 5.53 (1.17-26.2) 
 Intervention  ↑ 100 (7/7) <0.001 39.5 (2.21-709) 
Indeterminate Complication  ↑ 65 (24/37) <0.001 5.70 (2.62-12.4) 
 Ulceration  ↑ 46 (17/37) <0.001 3.53 (1.63-7.62) 
Focal Complication  ↓ 25 (34/139) <0.001 0.16 (0.08-0.32) 
 Ulceration  ↓ 19 (27/139) <0.001 0.20 (0.10-0.41) 
 Intervention  ↓ 27 (38/139) <0.001 0.18 (0.09-0.37) 
IH location      
Facial Complication  ↑ 47 (36/77) 0.005 2.39 (1.30-4.44) 
 Intervention  ↑ 53 (41/77) <0.001 3.25 (1.75-6.05) 
Neck Ulceration  ↑ 45 (9/20) 0.040 2.64 (1.02-6.84) 
Trunk Complication  ↓ 27 (22/82) 0.035 0.51 (0.27-0.96) 
Other factors      
Complication Intervention  ↑ 78 (51/65) <0.001 20.6 (9.51-44.8) 
Abbreviations: CI: Confidence Interval; OR: Odds Ratio; Preterm: <37gestational 
weeks 
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Table 9. Summary of IH characteristics that significantly either elevate or reduce 
long-term discomfort rate, evaluated on visual analogue scale (VAS) from 1 to 10. 
Re-printed and modified from the original article with the permission of John Wiley 
& Sons Ltd. 
 
Variable Long-term morbidity VAS 1-10 (95% CI) P value 
Long-term morbidity 
elevated    
      Any complication 3.0 (2.4-3.7) <0.001 
      Any intervention 2.9 (2.2-3.6) <0.001 
      Segmental subtype 4.8 (1.2-8.3) 0.004 
      Facial location 2.6 (2.0-3.1) 0.039 
      Indeterminate subtype 2.7 (1.8-3.7) 0.045 
Long-term morbidity 
reduced   
      Truncal location 1.6 (1.4-1.9) 0.009 
      Focal subtype 1.9 (1.6-2.2) 0.010 
Abbreviations: CI: Confidence Interval; VAS: Visual analogue scale 
 
 
Perinatal, gestational, and maternal risk factors 
Table 10 summarizes IH children’s perinatal, gestational, and maternal figures 
compared to the FMBR rates in 2004-2007 covering the same catchment area. In 
addition to other risks, maternal gestational diabetes was more common in the IH 
children’s mothers than listed in the FMBR (p=0.005, OR 2.62, 95% CI 1.39-4.95). 
Based entirely on hospital records and before sending the questionnaire, we were 
aware of 46% (6 of 13) of all GDM pregnancies, of 70% (16 of 23) of preeclampsia 
cases, of 44% (4 of 9) of IVF cases, of 20% (1 of 5) of placenta praevia cases, and of 
11% (2 of 18) of CVS. 
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Table 10. Perinatal, maternal, and gestational characteristics of the IH children in 
responses to the questionnaire: column I, (IH Q, n=136). All available data based on 
hospital records and questionnaire: column II, (IH all, n=185). Finnish Medical Birth 
Register data: column III (FMBR, n=70 842). P values, odds ratios (OR), and 95% 
confidence intervals (CI) are calculated between columns I and III by Chi-Square Test 
for univariate analysis, and by Mantel-Haenszel and heterogeneity tests for bivariate 
analysis. Re-printed and modified from the original article with the permission of 
John Wiley & Sons Ltd. 
 
Variable 
I 
IH Q 
II 
IH all 
III 
FMBR 
P 
value 
OR (95% CI) 
% % % 
Perinatal factors      
Female 73.5 72.4 49.0 <0.001 2.89 (1.98-4.22) 
Twins 12.4 10.9 3.0 <0.001 4.05 (2.38-6.89) 
Preterm infants 16.2 18.7 6.2 <0.001 2.93 (1.86-4.61) 
Very preterm infants 5.9 7.6 0.9 <0.001 6.70 (3.31-13.5) 
Birth weight <2500g 14.0 17.6 4.1 <0.001 3.76 (2.32-6.06) 
Apgar score ≤6 11.3 11.5 4.7 0.002 2.56 (1.47-4.55) 
Maternal and 
gestational factors      
Mothers aged ≥35 y 32.1 30.3 22.3 0.009 1.64 (1.15-2.36) 
First childbirth 55.9 55.9 45.6 0.020 1.51 (1.08-2.12) 
IVF  6.6 5.9 3.3 NS 2.09 (1.07-4.06) 
   IVF in mothers ≥35 y 16.3 14.9 6.6 NS 3.00 (2.76-3.23) 
CVS  8.3 8.3 2.4 <0.001 3.73 (2.03-6.86) 
   CVS in mothers ≥35 y 21.4 18.9 6.8 NS 6.55 (6.00-7.16) 
Placenta praevia 4.3 3.4 0.3 <0.001 13.4 (5.58-32.3) 
GDM 7.4 8.2 3.0 0.005 2.62 (1.39-4.95) 
   GDM in mothers ≥35 y 9.3 11.8 4.9 NS 2.10 (1.85-2.37) 
PE 10.4 14.3 2.4 <0.001 4.70 (2.71-8.15) 
   PE in mothers ≥35 y 14.0 17.6 2.5 NS 1.05 (0.88-1.24) 
   PE in first childbirth  14.5 20.7 3.3 NS 2.08 (1.81-2.38) 
Maternal smoking 9.7 10.1 13.6 NS 0.61 (0.34-1.10) 
Maternal β-blocker use 3.7 4.3 0.7 <0.001 5.56 (2.33-13.3) 
Abbreviations: CVS: chorionic villus sampling; FMBR: Finnish Medical Birth 
Register; GDM: gestational diabetes mellitus; IH: infantile haemangioma; IVF: in 
vitro fertilization; NS: nonsignificant statistical difference; OR: odds ratio; PE: 
preeclampsia; Preterm: < 37 gestational weeks; Very preterm: < 32 gestational weeks 
or < 1500 g; y: years. 
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Inheritance of IH  
Of the whole cohort, information on IH family history was available in 141 cases; in 
50 (35%) families it was positive, of which in 34 (68%) cases the closest affected was 
a first-degree relative. Among those 136 IH families who responded to the 
questionnaire, 46 (34%) of the families reported a positive family history of IH.  
 
Comparison of IH characteristics and risk factors in familial and sporadic IHs 
IH characteristics and risk factors between all familial cases and sporadic IH cases 
were closely similar. Only the number of identical twins between the groups differed, 
as all three monozygotic twins of this cohort also had first-degree relatives with IH, 
whereas no monozygotic twins appeared in the sporadic IH group (p=0.046, OR 21.0, 
95% CI 1.05-418.2). Because of the low number of monozygotic twins in the cohort, 
the confidence interval became large. IH patients with IH-positive first-degree 
relatives reported a significantly higher long-term discomfort rate (2.52, 95% CI 1.87-
3.16) than did the sporadic cases (2.03, 95% CI 1.64-2.42), p=0.036.  
 
Families with many IH-affected members 
Of the 46 families reporting positive family history of IH, we only reached 40, as 3 
did not allow re-contact, and 3 were unreachable. The number and characteristics of 
IH-affected family members are in Table 11. IH number, location, and subtype did 
not seem to correlate between IH-affected members within the same family. Of note, 
one index IH patient with a periorbital IH had an identical twin sister with an IH in 
exactly the same location (see Figure 2 in article 2. in the Appendix). No clear 
clustering of other inherited diseases or syndromes was observable in these families.  
 
 
Table 11. Summary of IH-affected families. 
 
Characteristics of 40 families with several IH-
affected members 
N (%, or median and 
range) 
Average number of IH-affected members per pedigree 3 (2, 2-13) 
Number of all IH-affected family members, excluding 
the index IH patient 
81 
   Number of IH-affected women 59 (73) 
   Number of IH-affected men 22 (27) 
Mother of the index patient with an IH 13 (33) 
Father of the index patient with an IH 4 (10) 
Pedigrees including first-degree relatives 25 (63) 
Pedigrees including second-degree relatives 10 (25) 
Pedigrees including more distant relatives 5 (12) 
Pedigrees with maternal side of family affected 22 (55) 
Pedigrees with paternal side of family affected 12 (30) 
Pedigrees with only siblings affected 6 (15) 
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Of the 40 families, 11 had 4 or more IH-affected family members. Pedigrees with four 
or more affected first- or second-degree relatives (Figure 21) indicated that the 
transmission seemed to follow an autosomal dominant inheritance pattern with 
incomplete penetrance: in one pedigree (no. 28), the father had transmitted the IH to 
three of his four children, suggesting strong dominant transmission. In ten pedigrees, 
however, the inheritance pattern could also indicate maternal transmission with 
incomplete penetrance.  
 
Geographic clustering 
The places of birth of the affected families’ grandparents ranged widely throughout 
Finland, as would be expected, clustering in southern Finland, corresponding to our 
hospital-district area. Nevertheless, many grandparents originated from low-
population eastern Finland. We observed, however, no clear founder effect nor 
geographic clustering. 
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Figure 21. Pedigrees of cohorts having four or more family members with an IH. Re-
printed and modified from the original article with the permission of American 
Academy of Pediatrics. 
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IH-related diseases, syndromes, and inherited diseases of the cohort 
Atopic disease occurred in the whole cohort in 22% of these children; it was equally 
frequent in children with and without a positive IH family history. One IH child in our 
cohort had PHACES syndrome, and another child presented with Sotos syndrome 
(cerebral gigantism), each with a negative IH family history. One girl had Turner’s 
syndrome, as well, and her mother also had had an IH. Other genetic disorders within 
our IH cohort, with no IH family history, were APC resistance and type 1 
neurofibromatosis, each affecting only one child.  
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8.2.  Sclerotherapy for venous malformations 
 
Complications occurred in 13 (17.3%) head-and-neck VM patients and were 
subjected to 15 sclerotherapy sessions (10.0%). For trunk-and-extremity VM, 
complications affected 31 (24.4%) patients, and occurred in relation to 35 (12.5%) 
sclerotherapy sessions. Demographic characteristics were similar between the 
complicated and non-complicated patients. For head and neck VMs, those who 
suffered from any complication also underwent more sclerotherapies (p=0.009), 
needed more surgery after sclerotherapy (p=0.007), and had longer clinical follow-up 
after sclerotherapy (p=0.01). Table 12 summarises the VM patient characteristics, 
sclerotherapies, other treatments, and follow-up. 
 
Table 12. Summary of venous malformation (VM) patient characteristics and 
sclerotherapies during the follow-up period for head and neck (H&N) and trunk and 
extremity (T&E) VMs. Re-printed and modified from the original articles with the 
permission of Springer and SAGE Publications. 
 
Variable 
H&N 
N (%) or median 
(range) 
T&E 
N (%) or median 
(range) 
Patients 75 127 
Females 51 (68.0) 73 (57.5) 
Males 24 (32.0) 54 (42.5) 
Total number of sclerotherpies in the cohort 150 280 
Sclerotherapies per patient 1.0 (1-13) 2.0 (1-10) 
Age (years) 33.0 (3-75) 21.5 (3-76) 
Surgery prior to sclerotherapy 27 (36.0) 29 (22.8) 
Surgery after sclerotherapy  6 (8.0) 10 (7.9) 
Clinical follow-up (months) from first session 6.0 (0-80) 35.0 (0-82) 
 
 
Sclerotherapy outcome was assessed only for head and neck VMs. Due to the 
retrospective study setting, outcome evaluation was limited to hospital records. Of 
those VM patients without complications, only 10 (16%) had a non-satisfactory 
outcome with further sclerotherapy planned, only 4 (6%) needed other treatment 
modalities due to non-satisfactory sclerotherapy outcome, and only 1 (2%) had a non-
satisfactory outcome without further treatment modalities scheduled at the time of the 
research. Of those VM patients with complications, 2 (15%) receive further 
sclerotherapies despite unsatisfactory sclerotherapy outcome thus far, 4 (31%) needed 
other treatments after sclerotherapy, and 1 (8%) has an unsatisfactory outcome with 
no other recommendable treatment modalities. The cohort’s average follow-up from 
hospital records from the last sclerotherapy to the time of this study was 36 months 
(median 35 months, range 4-81 months). 
 
?? ??
  
VM locations and tissue planes 
For head and neck VMs, the location and tissue involvement between those who 
suffered from a complication and those with no complication did not differ (Table 
13). Lesions involving the orbit and traversing many tissue planes were rare but did 
show relatively high complication rates. No statistically significant difference 
appeared. Those complications related to orbital VM lesions included prolonged 
swelling and pain and transient colour blindness with eye-muscle palsy.  However, in 
trunk and extremity VMs, the complication risk for subcutaneously located lesions 
was significantly higher than for those with deeper lesions with an intramuscular 
component (p=0.049). 
 
 
Table 13. Summary of localisation and tissue involvement of the venous 
malformations in head and neck (H&N) and trunk and extremity (T&E) cohorts. Re-
printed and modified from the original articles with the permission of Springer and 
SAGE Publications. 
 
Variable H&N  
N (%) 
T&E  
N (%) 
Location   
Lower face 5 (6.7)  
Mid-face 18 (24.0)  
Upper face 2 (2.7)  
Orbital extension 3 (4.0)  
VM with orbital connection 3 (4.0)  
Oral cavity 23 (30.7)  
VM with oral cavity connection 16 (21.3)  
Neck 5 (6.7)  
Trunk  15 (11.8) 
Upper extremity  50 (39.4) 
Lower extremity  62 (48.8) 
Tissue plane   
Subcutaneous / -mucous 33 (44.0) 59 (46.5) 
Intramuscular 13 (17.3) 64 (50.4) 
Intraosseal 2 (2.7) 5 (3.9) 
Intra-articular  4 (3.2) 
Intra-abdominal, retroperitoneal  2 (1.6) 
> 1 tissue plane involved 27 (36.0)  
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Sclerosing agents 
STS and polidocanol were the sclerosants most commonly applied. Use of ethanol, 
bleomycin, or doxycyclin was rare. Ethanol was mainly combined with other 
sclerosants. In sclerotherapies for head and neck VMs, we observed no significant 
difference regarding the sclerosant’s complication risk. For trunk and extremity VMs, 
sclerotherapies that involved the ethanol produced significantly more complications 
than did detergent sclerosants (STS and polidocanol) (p=0.019) (Table 14).  
 
 
Table 14. Summary of sclerosing agents and respective complication rates used in 
sclerotherapies for head and neck (H&N) and trunk and extremities (T&E) venous 
malformations. 
 
Sclerosant H&N  T&E  
 Number of 
procedures 
(total n=150)  
Number of 
procedures 
with 
complications 
(%) 
Number of 
procedures 
(total n=280) 
Number of 
procedures 
with 
complications 
(%) 
STS  96 7 (7.3) 189 21 (11.1) 
Polidocanol  17 1 (5.9) 51 6 (11.8) 
STS and 
polidocanol 
combined 
12 0   
Ethanol only 1 0 3 2 (66.7) 
Ethanol in 
combination 
7 2 (28.6) 16 5 (31.3) 
Bleomycin only 3 1 (33.3) 4 0 (0.0) 
Bleomycin in 
combination 
10 3 (30.0) 12 1 (8.3) 
Doxycycline 2 1 (50.0) 1 1 (100.0) 
Detergent 
sclerosant, not 
specified 
2 0 4 0 
Abbreviations: n=number of patients; STS: Sodium tetradecyl sulphate. 
 
 
Complications in sclerotherapy 
Complications affected altogether 44 VM patients and occurred in 51 sclerotherapy 
sessions during the follow-up period (Table 15). For head and neck VMs, 80%, and 
for trunk and extremity VMs, 83% of complications were graded I to II and resolved 
without treatment or with conservative methods. We discuss below the grade III and 
IV complications. 
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Table 15. Summary of sclerotherapy complications, graded according to the Clavien-
Dindo classification from I to V. Re-printed and modified from the original articles 
with the permission of Springer and SAGE Publications. 
 
Location Complication Management N Grade 
(I-V) 
H&N Unusual and prolonged hematoma 
and swelling 
Not necessitated 3 I 
H&N Partial facial nerve palsy Not necessitated 1 I 
H&N Mucous necrosis in the oral cavity Not necessitated 2 I 
H&N Partial palsy in the superior rectus 
eye muscle with transient colour 
blindness 
Not necessitated 1 I 
H&N Prolonged pain Analgesics 1 Id 
H&N Numbness of the lip / tongue Not necessitated 2 I 
T&E Skin damage Not necessitated 8 I 
T&E Pain or swelling or both for > 2 
weeks 
Analgesic and/or compression 
garment 
6 I 
T&E Thrombophlebitis external to VM Not necessitated 3 I 
T&E Unusual pain and transient sensory 
loss 
Analgesic 1 I 
T&E Unusual swelling and loss of range 
of joint motion 
Physiotherapy 1 I 
T&E Pain, swelling, skin damage and loss 
of range of motion 
Analgesic, physiotherapy 1 I 
T&E Loss of digital joint motion Physiotherapy 1 I 
H&N Infection and abscess of the 
injection site 
Bedside revision and oral 
antibiotics 
1 II 
H&N Mucous ulceration and infection Oral antibiotics 1 II 
T&E Skin damage, infected Oral antibiotics 4 II 
T&E Allergic reaction Corticosteroids, antihistamine 3 II 
T&E Intra-abdominal bleeding, mild Blood transfusion (one unit) 1 II 
T&E Deep vein thrombosis at ankle level LMWH medication 1 II 
T&E Skin damage Skin graft under local anaesthesia 2 IIIa 
H&N Partial necrosis of the maxillary 
bone and 3 teeth, infraorbital nerve 
injury 
Surgical removal of the necrotic 
tissue 
1 IIIb 
H&N Deep skin and frontal muscle 
necrosis, partial facial nerve palsy 
Several surgical revisions and skin 
grafting. 
1 IIIb 
H&N Severe bleeding of the tongue, 
partial tongue necrosis, sepsis 
Embolization, surgical removal of 
the necrotic tissue, iv antibiotics 
1 IVa 
T&E Injection site bleeding, sepsis, 
abscess, worsening of DIC 
Blood and coagulation factor 
transfusion, abscess drainage, iv 
antibiotics, ICU treatment, 
prolonged hospitalization 
1 IVb 
T&E Injection site bleeding, sepsis and 
skin damage 
ICU treatment and prolonged 
hospitalization, iv antibiotics 
1 IVb 
T&E Massive intra-abdominal bleeding Intra-arterial embolization, blood 
transfusion, ICU treatment 
1 IVb 
T&E Lethal intracerebral haemorrhage  1 V 
Abbreviations: H&N: head and neck; ICU: intensive care unit; LMWH: low-
molecular-weight heparin; T&E: trunk and extremity. 
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Severe complications of sclerotherapy  
A 29-year-old woman had a submucosal VM in her palate causing some discomfort 
before any interventions. She underwent one sclerotherapy with STS. Despite the 
seemingly normal course of sclerotherapy, occlusion of the internal maxillary artery 
and its peripheral vascular bed occurred. This resulted in necrosis in the maxilla, and 
three teeth, requiring surgical removal of the necrotic tissues, graded as a IIIb 
complication. As a result, she has a permanent bone defect, allodynia, and infraorbital 
nerve injury (Article III). 
 
A 31-year-old woman suffered from episodes of headaches due to a large 
subcutaneous and intramuscular VM in the temporal region, one that was connected 
to intracranial veins. She had undergone surgery almost 20 years prior to 
sclerotherapy. Her first sclerotherapy was successful but not sufficient for symptom 
relief. After the second scleotherapy with STS, without any deviation from the normal 
procedure, she developed first a facial nerve palsy and then skin and muscle necrosis 
in the frontotemporal area. These complications necessitated several revisions and 
correction with a skin graft, and later scar corrections. Other functions of the facial 
nerve recovered, but her right frontal muscle function was lost. Partial hair loss 
occurred in the grafted temporal scalp area. The mechanism of the complication 
remains unclear but may have been related to the tissue toxicity of STS. We 
considered this to be a grade IIIb complication (Article III). 
 
A large intramuscular VM in the tongue caused functional impairment of eating and 
speaking for a 69-year-old man with diabetes type 2 who was on acetylsalicylic acid 
medication. To avoid extensive swelling near the airways, the sclerotherapy was 
primarily performed with bleomycin. During the session, an unexpected bleed 
occurred from a large area of tongue’s capillary bed. His tongue was compressed with 
a thrombin product, and ethanol and STS were also injected to create swelling and 
compression. Despite these measures, the bleed continued and necessitated 
catheterization of the right lingual artery and injection of embolizing particles into the 
capillaries. This led to partial tongue muscle necrosis and infection. He developed 
sepsis, required intravenous antibiotics and surgical removal of the necrotic tissue, 
resulting in permanent partial loss of the tongue. The patient suffers from some 
problems with articulation, but is satisfied with the overall result. We considered this 
to be a life-threatening complication and single organ dysfunction, thus, earning a 
grade IVa complication (Article III) 
 
A large and diffuse retroperitoneal VM in a paediatric patient necessitated 
intervention; untreated it caused the patient severe consumption coagulopathy. The 
lesion was considered inoperable. Following a dorsal needle puncture of the VM, he 
developed a severe intra-abdominal bleed from the left phrenic artery. The bleed 
necessitated intravascular embolization and hospitalization in the intensive care unit. 
?? ??
Despite this complication, he underwent thereafter several sclerotherapies to achieve 
stabilization of the VM-induced coagulopathy (Article IV). 
 
A young man suffered from a very extensive VM in the lower body and right leg, 
causing severe consumption coagulopathy and resulting in pulmonary embolism and 
life-threatening bleedings due to very low fibrinogen levels prior to sclerotherapy. 
The VM was considered inoperable because of the high risk of bleeding. The case 
was thoroughly discussed in our interdisciplinary team together with a haematologist, 
because the complication risk during scleortherapy was regarded very high. An 
intervention was necessary to control the coagulopathy and to facilitate further 
surgery. During two separate sclerotherapies, he suffered from serious infections. 
Following the first sclerotherapy with polidocanol and ethanol combined with NBCA 
glue and laser treatment, severe bleeding occurred at the injection site, leading to a 
large haematoma, infection, and sepsis necessitating intravenous antibiotics and 
prolonged hospitalisation. After the second sclerotherapy combined with laser and 
NBCA glue, the intravascular coagulopathy worsened, leading to bleeding, abscess 
formation, and septic infection, necessitating blood and coagulation transfusion and 
intravenous antibiotics. Currently, after several successful sclerotherapies, the VM-
induced coagulopathy is under control, and he is scheduled for surgery to reduce the 
VM mass (Article IV). 
 
Another severe sclerotherapy complication was also related to severe consumption 
coagulopathy: a young woman suffered from a VM covering her entire upper limb 
and axilla. The limb was completely unusable. The VM caused her severe 
consumption coagulopathy, treated with regular low-molecular-weight heparin 
injections. The sclerotherapy indications included control of the coagulopathy and 
facilitation of further surgery to improve the limb’s function. The treatment was 
carefully planned with a haematologist, and sclerotherapy with STS 3% combined 
with NBCA glue was performed with simultaneous coagulation monitoring. Despite 
all precautions, after sclerotherapy she developed a multifocal intracerebral 
haemorrhage, most likely due to the severe and uncontrollable coagulopathy, and 
died. Neuropathological autopsy revealed no other condition that could have 
predisposed this patient to such a haemorrhage (Article IV). 
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9. Discussion 
 
Despite extensive research on the pathogenesis, genetics, risk factors, and treatment 
of vascular anomalies, many unsolved questions still remain. This study concentrated 
on the two most common types of vascular anomalies: infantile haemangioma and 
venous malformation.  
 
 
9.1. Infantile haemangioma: risk factors, long-term 
discomfort, and inheritance 
 
Infantile haemangioma most likely has a multifactorial origin. Its main determinants 
and strongest causative risk factors remain, however, speculative. Studies suggest that 
the strongest risk factor is low birth weight (46). Other proposed risk factors mainly 
overlap, and usually occur simultaneously (Table 2). Independent risk factors 
documented are at least low birth weight and gender (8,9,46,102).  
 
IH risk factors 
The figures on maternal gestational diabetes in IH children’s mothers are only 
presented in one study from China (52). Our study population significantly differs 
from that Chinese cohort. GDM is, however, a common and an increasing pregnancy 
complication in most western countries (229). GDM occurred more often in our IH 
cohort’s mothers than in the FMBR in our hospital district. Due to differing data 
sources, we could not conduct a multivariate analysis to segregate independent risk 
factors; this association therefore remains uncertain. GDM works, however, in 
opposition to the known IH risk factors, as it usually leads to elevated birth weight, 
although in some reports it has been linked to preterm delivery (230).  
 
Intrauterine glucose metabolism plays an important role in angiogenesis, because 
sprouting endothelial cells (ECs) rely for their ATP production mostly on glucose-
consuming anaerobic glycolysis (231,232). Diabetic pregnancies could favour this 
glycolytic activity of ECs in the same manner as hypoxia does, by inducing angio- 
and vasculogenesis (53,231,233). Additionally, escaping apoptosis is one of the key 
mechanisms in IH proliferation, because proliferating IH specimens show up-
regulation of anti-apoptotic proteins (56,79). Gestational diabetes favours reduced and 
impaired apoptosis in placental trophoblasts, the potential source of IH stem cells: this 
process may promote anti-apoptosis and therefore the intrauterine development of IH 
(56,234). The link between GDM and IH is unclear and requires further study, as this 
may reveal missing links in the pathogenesis of IH.  
 
IH complications   
Even if most IHs resolve without complications and intervention, some lesions can 
lead to significant and even life-threatening complications necessitating substantial 
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treatment and resulting in elevated levels of long-term discomfort (102,127,150). In 
our study, the IH complication rate was 35%, and the intervention rate 37%; these 
rates are obviously higher than in the general IH population, because we studied a 
hospital cohort. The predisposing factors for complications and interventions mostly 
conformed to those previously reported: facial location and segmental and 
indeterminate IH subtypes are associated with increased risk (102,127). We 
discovered that preterm birth predisposed the child to ulceration, the most common IH 
complication. No previous studies show this correlation, but it is relevant for 
physicians treating IH infants, and may help us to anticipate complications in preterm 
infants (235,236).   
 
Long-term discomfort resulting from IH 
IH-induced long-term discomfort is little studied (150-152). The overall level of long-
term discomfort in our study was relatively low, the average for the whole cohort 
being 2.31 on the VAS scale. This finding is in accordance with earlier findings of 
quality of life in IH and in non-IH children (151). We found that facial location, 
segmental but also indeterminate subtypes, history of complication, and intervention 
caused increased long-term discomfort rates. In contrast, focal and truncal IHs 
produced lower discomfort rates. Additionally, those IH patients with a first-degree 
relative with IH also reported elevated discomfort rates compared to rates for sporadic 
IH cases. Chamlin and colleagues reported decreased quality of life levels for children 
younger than 19 months with a head and neck IH, or for those undergoing IH-related 
interventions (150). IH children in our cohort were on average ten years old at the 
time of the questionnaire, and their IHs had reached full involution. Long-term 
discomfort assessment is therefore relevant at this age. Future studies will show 
whether current β-blocker therapies have an effect on long-term outcome and patient 
satisfaction (126).  
 
Inheritance of IH 
Despite the frequency of IHs, its inheritance is relatively little studied, even though 
one known risk factor is familial clustering (54,85,86,89). Based on our study setting, 
we are unable to state the true proportion of familial IH cases, but we show that a 
significant number of IHs involve familial clustering: more than one-third of our 
patients had a relative with an IH, and one-fourth had a first-degree relative with IH. 
This rate was somewhat higher than in earlier reports that estimate familial clustering 
to be present in 10 to 20% of IH cases (8,12). No studies previous to ours have 
assessed the potential differences between familial and sporadic IHs. We found that 
familial and sporadic cases were similar in IH characteristics and risk factors, 
indicating that familial predisposition does not promote any specific IH subtype or 
localisation. To our knowledge, however, a case of monozygotic twins with IHs in 
identical location has never been reported before.  
 
To evaluate the true incidence of familial IH remains difficult, because of the nature 
of IH and its multifactorial origin; some affected family members may actually 
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represent IH phenocopies, meaning sporadic IHs, because they may have an IH due to 
risk factors other than familial predisposition (87,91,237). Because of similar features 
between familial and sporadic IHs, it was impossible to differentiate between these 
phenocopies. Therefore, further genetic studies are necessary to understand the role of 
genetic predisposition in IH pathogenesis. 
 
The inheritance pattern of infantile haemangioma in our study mainly followed an 
autosomal dominant inheritance pattern with incomplete penetrance, supporting 
earlier findings. Future genetic studies will most likely reveal whether these families 
also show a linkage to chromosome 5q, as shown by Walter, Blei and colleagues, or 
show other, possibly angiogenesis-related, germline mutations (54,85,86,89). 
Additionally, we found families in which the IH may have been maternally 
transmitted, leading to the question whether the genetic variations could locate in 
mitochondrial genes. Little is known regarding the role of mitochondria in IH 
pathogenesis: only one report has studied the mitochondria in IHs, with an emphasis 
on the mitochondrial apoptotic pathway, important for the involution of IH, but not 
regarding IH development (238). Of note, neither a mitochondrial nor any other 
specific disease was observable in these IH children or in their families. Further 
investigations are required to find the genetic mutations related to IH’s familial 
clustering, and to identify whether they indicate autosomal dominant or maternal 
transmission. 
 
Limitations of IH studies 
Our study was limited to a hospital-based patient cohort representing more difficult 
IH cases, and this most likely accentuates our complication and intervention rates for 
IH, as excluding the innocuous IHs followed in primary health care. The 
questionnaire-based information relies in part on parental recall. However, virtually 
all pregnancies and newborns are followed in our primary health care system that 
adheres to national guidelines for pregnancy-related and perinatal data and reports 
them to the FMBR. Each mother has a personal maternity card containing all data on 
the course and complications of pregnancy; mothers are therefore well aware of their 
pregnancy-related data. Tracing the pedigrees of index IH patients with a positive 
family history was firstly based on the parents’ memory. We questioned the IH-
affected families first with the written questionnaire and thereafter confirmed this 
information in detail in the phone interview, where we specifically asked whether the 
IH of an affected family member had followed the typical clinical course. We were 
unable to acquire reference data by sending the questionnaire to a randomly selected 
population because of misuse of the term “haemangioma”, which would have 
produced both false-negative and false-positive cases (5,15,42). Therefore, the 
reference material regarding perinatal information came from the FMBR, which 
limited the study.  
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9.2. Complications of sclerotherapy for venous 
malformations 
 
The second main objective was to determine treatment complications of 
sclerotherapy, the most common treatment modality for VMs, by use of a 
standardized Clavien-Dindo complications classification. These studies revealed that 
most complications resolve with conservative methods, but severe and even fatal 
complications may occur. Because we are treating a non-malignant disease, critical 
assessment of complication risks is vital. The heterogeneity of VM lesions 
necessitates that the sclerotherapy indication for each patient must be viewed 
individually. 
 
What is a sclerotherapy complication? 
The complication rates of sclerotherapy for VMs range from 0 to 65%, depending on 
the study setting and complication-reporting threshold 
(206,208,209,212,217,219,239-255). Most of these studies involve a relatively small 
patient number and concern ethanol sclerotherapy, which is currently less frequently 
used, due to its side-effects, or they combine, as we did as well, different sclerosants, 
which makes the comparison of different studies challenging. Moreover, the 
definition of a sclerotherapy complication is unclear, as some studies only consider 
permanent or systemic complications and neglect less severe complications such as 
prolonged pain, swelling, and ulceration. For example, Berenguer, a pioneer in 
sclerotherapy treatment, and his colleagues reported acute blistering (50%), very 
common after sclerotherapy, as a complication, whereas several other studies only 
report on major complications.  Considering these limitations, our complication rates 
of 17% for head-and-neck and 24% for trunk-and-extremity VMs respectively are 
generally in accordance with these findings. We report here all adverse events that 
had been documented in patient records. To date, no consensus exists to differentiate 
between a sclerotherapy complication and an expected side-effect of the treatment. 
 
Classification of sclerotherapy complications 
When evaluating outcomes and complications of any treatment, utilisation of a 
standardised classification tool is vital: it permits objective comparison among studies 
and leads eventually to a more robust consensus on any treatment’s advantages and 
disadvantages. To our knowledge, this is the first study that has utilised a standardised 
classification for sclerotherapy complications.  The Clavien-Dindo classification 
overcomes the use of the subjective terms “minor” and “major” complications, as its 
grading is based on what further procedures the complication necessitates, rendering 
the evaluation very objective (214-216). The Clavien-Dindo classification may, 
however, give a low grading and therefore overlook complications that result in 
permanent morbidity, such as nerve injuries and prolonged pain, non-curable by any 
intervention. When the aim of treating VMs is symptom-relief, these types of 
complications should be taken seriously. In our view, the Clavien-Dindo 
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classification, despite its weaknesses, represents a more objective complication-
grading system than is the SIR grading that categorizes complications as minor or 
major (213). We propose therefore that the Clavien-Dindo classification is an 
appropriate candidate to be applied in future studies concerning sclerotherapy 
complications.  
 
VM characteristics and complication risk 
In our studies, VM location was not a significant factor regarding the patient’s 
complication risk. In the head-and-neck cohort, VMs involving the orbit or oral cavity 
and those lesions penetrating several tissue layers resulted proportionally more often 
in complications, but due to the small patient number, with no statistically significant 
difference. A previous study has also addressed the treatment challenge of orbital 
VMs and shown positive results from pingyanmycin, similar to bleomycin, in 
sclerotherapy for periorbital lesions, as it causes the least swelling and has therefore 
fewer side-effects due to the confined location (256). Therefore, VM location should 
have an impact on sclerosant choice. For a trunk-and-extremity VM patient, location 
itself was not a determinant factor regarding the complication risk, but subcutaneous 
VM location was: it predisposed more to skin necrosis than did other tissues. This 
finding is in accordance with previous findings: subcutaneous VM location is a risk 
factor for local skin necrosis in sclerotherapy treatment (241,242).  
 
Choice of sclerosant and complication risk 
The choice of sclerosant most probably has an impact on complication risk. For trunk 
and extremity VMs, use of ethanol was linked to higher complication risk and 
produced mainly local skin necrosis, as also reported earlier (239,241,242). A recent 
review on different sclerosants agrees with this finding: ethanol produced more skin 
and neural damages as well as systemic side-effects than did other sclerosants (203). 
Ethanolamine oleate was reportedly the most efficient sclerosant, but also produced 
the highest rate of renal and muscle damage. Due to different study settings, outcome, 
and complication measurements, objective assessment of the efficacy and safety 
between sclerosants is difficult. The current consensus states, however, that ethanol 
should be avoided when possible, because of its potentially serious side-effects 
(202,203). The development of a new gel-like sclerosant, as reported by Schumacher 
and colleagues, may provide a solution to this issue (207).  
 
Complication mechanisms in sclerotherapy 
To avoid complications, it is crucial to understand their potential mechanisms. 
Sclerosants are toxic agents, targeted at the damage and scarring of endothelial cells 
(173); sclerosant extravasation outside of the VM causes tissue injury and may lead to 
adjacent tissue necrosis. Reflux of the sclerosants through capillaries has been 
reported as a potential complication mechanism (182). This may have been the 
complication mechanism in our frontal muscle necrosis and maxilla necrosis. 
Although we used a draining technique to avoid reflux and overfill of the VM, the rise 
in intraluminal pressure in these cases probably led to extravasation.  
?? ??
 
Nerve injuries were relatively rare in our studies, and mostly resolved. They are most 
commonly due to extensive swelling and nerve compression in confined locations 
(203,257). Post-procedural infections may also occur, even though rarely. In our study 
of trunk and extremity VMs, the infections were mainly related to therapies in which 
glue was used to close large venous spaces. As a foreign material, it may have 
provoked the infection. We therefore now tend to use prophylactic antibiotics for 
those patients who show pre-existing skin damage or are at risk for developing such 
damage, or for whom the use of glue as part of the therapy is indicated.  
 
Most of the severe complications related to sclerotherapy resulted from extensive 
bleedings and blood coagulopathy. The severe bleeding of the tongue VM was 
uncontrollable by any other methods, making the endovascular management the best 
available option in this emergency case, which unfortunately resulted in tongue 
necrosis and sepsis. The patient was on acetylic salicylic acid medication, and had 
normal coagulation factors, but may have suffered from local coagulopathy in the 
VM, presumably predisposing to the bleeding. Regarding severe complications for 
trunk-and-extremity VMs, all patients suffered from serious coagulopathy, which 
caused most of their complications. Even though VM-related coagulopathy is 
acknowledged as a known risk factor for complications, no systemic report exists 
regarding coagulopathy and sclerotherapy (258-260). Any VM-related coagulopathy 
should therefore be evaluated carefully together with a haematologist, and these VM 
patients should only be treated in centres prepared to manage potentially life-
threatening coagulation and bleeding complications. The sclerotherapy techniques, 
various scleorsants, and systematic complication- and outcome monitoring deserve a 
standardised measurement system to improve the safety and efficacy of sclerotherapy 
for venous malformations.  
 
Limitations of the study 
Our research was limited by its retrospective nature, rendering outcome measurement 
difficult. During the study period of 2007-2013, several varieties of needles, catheters, 
and vascular access kits have served for sclerotherapy, and the choice of equipment 
has been tailored for each procedure according to the VM characteristics and to the 
interventional radiologist’s preference. The HUH’s vascular anomaly team has set up 
a patient registry in which we collect all data on vascular anomaly patients and their 
treatment; this will facilitate further studies and analyses on treatment safety. The 
relatively low patient number prevented us from observing statistically significant 
differences in complication risks in relation to VM location, tissue involvement, and 
sclerosants. However, these studies on head and neck-, and trunk and extremitiy VMs 
receiving sclerotherapy make up one of the largest studies on this topic conducted to 
date.   
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10.  Future aspects 
 
The ever-increasing knowledge and understanding of vascular anomalies may in 
future allow more accurate diagnostics and tailored treatment of vascular anomalies. 
Infantile haemangioma causes a substantial burden for children, their families, and the 
healthcare system. Understanding its causative mechanisms may also provide means 
for prevention. For example, increasing use of non-invasive prenatal testing, which 
has resulted in a decrease in the number of CVS procedures, one proposed IH risk 
factor, could have some effect on IH incidence (261).   
 
Despite IH’s presumed multifactorial origin, research on its genetic background is 
essential. Our study on IH inheritance models and identification of families with 
several affected family members could facilitate future genetic studies. Elucidation of 
genetic causes will enlarge understanding of the pathogenesis of IH and will facilitate 
the development of new medical therapies.  
 
The treatment of venous malformations still constitutes an interdisciplinary challenge. 
Critical evaluation of treatment indication is vital, since not all complications can be 
avoided. New sclerosants and techniques are constantly developed to obtain better 
results with minimal complications (207,227). Nevertheless, assessment of VM-
related coagulopathy is necessary to avoid any serious side-effects. The increasing use 
of laser therapy may play a role in VM treatment when sufficient amounts of research 
data on its efficacy and safety are available (197,223,224,227).  
 
Medical therapy for venous malformations has dramatically evolved: rapamycin, an 
mTor inhibitor blocking the VM-causative signalling pathway, has been introduced in 
the treatment of VMs refractory to other treatments (169). It may offer relief for 
patients with difficult VMs, impossible to treat with other modalities. Future 
investigations will determine rapamycin’s role in VM therapy. A variety of treatment 
modalities will enable us to combine different therapies to obtain the best possible 
result for complex VM patients.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
?? ??
11.  Conclusions 
 
This study suggests that physicians treating children with infantile haemangiomas 
should consider the preterm IH infants’ higher risk for ulceration, and should 
especially direct attention to those IHs that result in increased long-term discomfort. 
Association between maternal gestational diabetes and the child’s IH risk is uncertain 
and calls for further study. In addition to autosomal-dominant transmission in familial 
IH cases, we propose that some IHs may be maternally transmitted.  
 
Sclerotherapy is rather safe for treatment of venous malformations. Critical evaluation 
of complications is nevertheless crucial; we found the Clavien-Dindo classification 
suitable for complication assessment. Sclerotherapy complications do occur but most 
recover with conservative methods. Complicated VM cases tend to necessitate more 
sclerotherapies, increasing these patients’ complication risk. The use of ethanol as 
sclerosant should be avoided due to its higher complication risk. VM-related 
coagulopathy constitutes a significant risk for sclerotherapy and may even lead to 
fatal complications.  
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